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Zusammenfassung 
Das Wechselspiel zwischen Viren und ihren Wirtszellen beginnt meist an pattern recognition-
Rezeptoren (PRRs), die für die Erkennung unterschiedlichster Pathogene anhand bestimmter 
Strukturen, sogenannten pathogen-associated molecular patterns (PAMPs), zuständig sind. 
Nach Detektion lösen die PRRs über verschiedene Signalkaskaden eine antivirale Antwort 
aus, die zur Expression antiviraler Gene führt. RIG-I und MDA5 sind zytoplasmatisch lokali-
sierte PRRs und erkennen RNA-Strukturen, die insbesondere während der viralen Replikation 
und Transkription verfügbar sind. 
Hantaviren sind humanpathogene RNA-Viren mit einem einzelsträngigen, segmentierten Ge-
nom. Die Konsequenzen hantaviraler Infektionen auf molekularer Ebene wurden bereits de-
tailliert untersucht, aber die Mechanismen, die zur Induktion der Immunantwort führen, wie 
auch mögliche Immunevasionsstrategien, die wahrscheinlich in Zusammenhang mit der Pa-
thogenität des jeweiligen Hantavirusstamms variieren, konnten bisher nicht identifiziert wer-
den. Da Hantaviren im Cytoplasma ihrer Wirtszellen replizieren, stellen RIG-I und MDA5 
potentielle Detektoren dar. 
In dieser Doktorarbeit wird die Bedeutung von RIG-I und MDA5 für die Erkennung von Han-
tavirus-Infektionen untersucht. Wachstumskinetiken zeigten, daß RIG-I die Replikation von 
pathogenen wie auch apathogenen Hantaviren beeinträchtigt. Außerdem konnte die RNA han-
taviraler Nukleocapsid- (N-) ORFs als eine virale Komponente identifiziert werden, die Typ I 
Interferon über RIG-I induziert. Das Ausmaß der Interferon-Aktivierung korrelierte hierbei 
tendenziell mit dem Virulenzgrad der Virusstämme und war für die nicht-pathogenen Hantavi-
ren nicht nachweisbar. Unterschiede in der Aktivierungsstärke können anhand vorläufiger 
Daten wahrscheinlich auf noch nicht identifizierte Motive zurückgeführt werden, die am 3’-
Ende der N ORFs liegen. Im Gegensatz dazu wurde keine Interferon-Aktivierung durch han-
tavirale Komponenten über MDA5 festgestellt.  
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Abstract 
Host-virus interaction is usually initated by pattern recognition receptors (PRRs) which are 
responsible for the recognition of various pathogens based on so-called pathogen-associated 
molecular patterns (PAMPs). Upon detection, PRRs trigger an antiviral immune response 
through different signalling cascades that lead to the expression of antiviral genes including 
interferon genes. RIG-I and MDA5 are cytoplasmically localised PRRs and recognise RNA 
patterns that are particularly available during viral replication and transcription.   
Hantaviruses are RNA viruses with single-stranded segmented genomes. The consequences of 
hantaviral infections have been analysed in detail, but the mechanisms that lead to the induc-
tion of the innate immune response as well as immune evasion strategies depending on the 
pathogenicity of the respective hantavirus strains have not been identified yet. Since hantavi-
ruses replicate in the cytoplasm of their host cells, RIG-I and MDA5 represent potential PRRs 
for hantaviral detection.  
This thesis investigates the impact of RIG-I and MDA5 on recognition of hantaviral infec-
tions. Growth kinetics show that RIG-I impairs the replication of pathogenic as well as non-
pathogenic hantaviruses. Furthermore, the RNA of hantaviral nucleocapsid protein (N) ORF 
could be identified as a viral component responsible for the induction of RIG-I signalling. It is 
shown that the degree of interferon promotor activation correlates with the virulence of the 
hantavirus strain from which the N ORF was derived. Based on preliminary data, differences 
in activation strength may be attributed to not yet identified motifs at the 3’ end of the ORF. In 
contrast, no interferon activation through MDA5 could be observed.  
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1 Introduction 
1.1 Hantaviruses 
1.1.1 Overview 
The earliest descriptions of diseases possibly caused by hantaviruses were recorded in the 
10th century (Lee, 1982). During the Korean War (1950-1953), many UN soldiers were hospi-
talised with Korean hemorrhagic fever, resulting in mortality rates up to 7% (Jonsson and 
Schmaljohn, 2001; Smadel, 1953), but the causative agent still was not discovered until 1978 
when the Hantaan virus (HTNV) was isolated from its reservoir host Apodemus agrarius, the 
striped field mouse (Lee et al., 2004).  
In 1981, HTNV was the first hantavirus adapted successfully to cell lines for in vitro experi-
ments. Taxonomic investigations showed that it belonged to the family of Bunyaviridae 
(White et al., 1982). The clinical feature of New World hantaviruses, called hantavirus cardio-
pulmonary syndrome (HCPS), was detected in 1993 (Peters and Khan, 2002). Until today 
other hantavirus species are being discovered in Europe, Asia, the Americas and Africa 
(Figure 1). 
New York (NY-1)
Prospect Hill (PHV)
Sin Nombre (SNV)
Andes (ANDV)
Hantaan (HTNV)
Puumala (PUUV)
Tula (TULV)
Dobrava (DOBV)
Seoul (SeoV)
Thottapalayam (TPMV)
 
Figure 1. Global distribution of selected hantavirus strains (first isolation habitat) 
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Nowadays, hantaviruses are classified as emerging viruses, 20 of them being pathogenic for 
humans (Clement, 2003; Peters and Khan, 2002; Jones et al., 2008; Kruger et al., 2001). Al-
though hantaviruses are categorised as potential biological warfare agent by the US Centers 
for Disease Control and Prevention (CDC) (Clement, 2003), few data exist about their interac-
tions with the immune systems of their hosts.  
Furthermore, there are no antiviral drugs for curing hantavirus infections, only symptoms can 
be controlled until convalescence. The guanoside-analog Ribavirin (1-β-D-ribofuranosyl-
1,2,4-triazole-3-carboximide) initially showed promising results for antiviral therapy 
(Huggins et al., 1986; Huggins et al., 1991) which, unfortunately, could not be confirmed 
(Chapman et al., 1999; Chapman et al., 2002; Maes et al., 2004; Rusnak et al., 2008). 
1.1.2 Taxonomy and morphology 
Hantaviruses as well as four other virus genera form the family of Bunyaviridae. They are 
renowned for their negatively-orientated single-stranded RNA genome that is separated into 
three segments. The segments in turn differ in sequence and size; the longest segment (L) en-
codes the RNA-dependent RNA polymerase (RdRp), the intermediate segment M contains the 
coding sequences for both glycoproteins G1 and G2 or Gc and Gn, respectively, and the 
shortest segment S codes for the nucleocapsid protein (Figure 2) (Dunn et al., 1995; Elliott, 
1990; Maes et al., 2004; Schmaljohn and Hjelle, 1997). Arvicolinae- and Sigmodontinae-
associated hantaviruses possess an additional open reading frame (ORF) within the S seg-
ment, coding for a putative non-structural (NS) protein (Bowen et al., 1995; Plyusnin, 2002). 
Each segment is closed non-covalently due to complementary structures at its highly con-
served 3’ and 5’ ends, thereby forming the typical so-called panhandle (Pardigon et al., 1982). 
Furthermore, the 5’ termini of HTNV genome segments contain uridine monophosphates 
(UMP) (Garcin et al., 1995). 
The enveloped virions have a diameter of approximately 120 nm and are spiked with the gly-
coproteins, G1 and G2, as heterodimers that mediate cell attachment and fusion (Arikawa et 
al., 1985; Lee and Cho, 1981; Martin et al., 1985; Obijeski et al., 1976; Okuno et al., 1986; 
Tsai, 1987). The virions contain the viral ribonucleoprotein complexes (vRNPs) consisting of 
the three genome segments (vRNA) attached to N protein trimers, thereby protecting the RNA 
from nuclease degradation (Alfadhli et al., 2001; Kaukinen et al., 2001). Furthermore, the 
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viral RdRp, that also functions as replicase, transcriptase and endonuclease, is associated with 
the vRNPs (Figure 2) (Elliott, 1990; Gott et al., 1993; Obijeski et al., 1976). 
100-120 nm
RdRp
N protein
vRNA
G1, G2 protein
S segment
M segment
L segment
 
Figure 2. Hantavirus virion: Hantaviruses consist of a double-layer lipid membrane carrying the G protein 
heterodimers. The three vRNA segments coding for the four viral proteins are complexed with N protein, build-
ing the vRNPs, and viral RdRp. 
1.1.3 Life cycle 
Hantaviruses known to be pathogenic to humans enter the cells through β3 integrins (CD61) 
as receptors, found e.g. on endothelial cells, platelets and macrophages, whereas non-
pathogenic hantaviruses use the ubiquitous β1 integrins (CD29) (Gavrilovskaya et al., 1998; 
Gavrilovskaya et al., 1999; Gavrilovskaya et al., 2002). Further receptors are supposed to be 
involved in hantavirus entry (Kim et al., 2002; Krautkramer and Zeier, 2008; Choi et al., 
2008).  
Entry takes place via clathrin-dependent endocytosis, mediated by the viral glycoproteins (Jin 
et al., 2002). After release of vRNPs into the cellular cytoplasm, cRNAs, full-length comple-
mentary strands of each segment, are synthesized, serving as templates for vRNA synthesis. 
mRNAs are also transcribed by the viral RdRp after accumulation of vRNA and matured by 
the so-called “cap-snatching” mechanism, i.e. the viral polymerase cleaves methylated 5’ caps 
from cellular mRNAs and attaches them to the viral mRNAs (Dunn et al., 1995; Garcin et al., 
1995; Elliott et al., 1991).  
At first, the N proteins as well as the RdRp are translated in the cytoplasm at free ribosomes 
and accumulate (Alfadhli et al., 2001; Kaukinen et al., 2001; Schmaljohn and Hjelle, 1997). 
After synthesis of the glycoprotein precursor at the endoplasmic reticulum, the precursor is 
cleaved into two glycoproteins G1 and G2 (Lober et al., 2001). These are in turn transported 
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to the Golgi apparatus for glycosylation and accumulate as heterodimers (Ruusala et al., 1992; 
Shi and Elliott, 2002), ready for building new virions with the vRNPs.  
It has not been elucidated yet where the following assembly steps take place and how the viri-
ons leave the cells. The majority of the Bunyaviridae mature by budding into the Golgi cister-
nae (Ellis et al., 1988; Hobman, 1993; Jantti et al., 1997; Kuismanen et al., 1985; Rwambo et 
al., 1996), but some New World viruses also mature at the cell surface. For example, Sin 
Nombre virus (SNV) has been found to bud at the plasma membrane (Goldsmith et al., 1995; 
Ravkov et al., 1997; Ravkov et al., 1998). After maturation, the virions exocytose from the 
host cells through vesicles and are released into the cellular environment (Figure 3). 
1..
5..
cRNAcmRNA
vRNA
6..
3..
2..
4..
7..
 
Figure 3. Replication cycle of Bunyaviridae (after Schmaljohn and Hooper 2001): 1. Entry, 2. Transcription, 3. 
Translation, 4. Replication, 5. Assembly, 6. Alternative assembly, Egress, 7. Egress 
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1.1.4 Phylogeny and hosts 
To date, more than 30 hantavirus species have been discovered (Hart and Bennett, 1999; Kan-
erva et al., 1998; Plyusnin, 2002). The strict reservoir host specificity of hantaviruses is re-
markable, indicating a stringent co-evolution of virus and host (Hjelle and Yates, 2001; Plyus-
nin and Morzunov, 2001; Plyusnin, 2002). The Old World viruses from Asia and Europe like 
HTNV, Puumala virus (PUUV), Seoul virus (SEOV) and Dobrava virus (DOBV) are mainly 
Murinae- and Arvicolinae-associated, whereas New World viruses found in the Americas are 
often carried by Sigmodontinae. Furthermore, latest investigations revealed insectivores as 
additional reservoir hosts next to the known rodent classes (Table 1) (Carey et al., 1971; Ya-
nagihara and Silverman, 1990; Song et al., 2007; Klempa et al., 2008; Rusnak et al., 2008). 
 
Table 1: List of selected hantaviruses 
Species Abbreviation Rodent host Distribution Disease Case 
fatality 
Murinae-associated      
Dobrava Belgrade 
virus 
DOBV (Aa) Apodemus agrarius Central and East 
Europe 
HFRS 0.9% 
 DOBV (Af) Apodemus flavicollis South-East Europe HFRS 9-12% 
 DOBV (Ap) Apodemus ponticus South-East Europe HFRS 6.5% 
Hantaan virus HTNV Apodemus agrarius Asia HFRS ≤ 15% 
Seoul virus SEOV Rattus norvegicus Asia HFRS 1-2% 
Arvicolinae-
associated 
     
Prospect Hill virus  PHV Microtus pennsyl-
vanicus 
North America - - 
Puumala virus PUUV Clethrionomys 
glareolus 
Eastern and South-
ern Europe 
HFRS 
(mild) 
< 1% 
  Clethrionomys rufo-
canus 
   
Tula virus TULV Microtus arvalis Central and East 
Europe 
? ? 
  Microtus rossi-
aemeridionalis 
   
Sigmodontinae-
associated 
     
Andes virus ANDV Oligoryzomys longi-
caudatus 
Argentina HCPS 43-56% 
New York virus NYV Peromyscus leuco-
pus 
North America HCPS ? 
Sin Nombre virus SNV Peromyscus manicu-
latus 
North America HCPS 35% 
Insectivore-
associated 
     
Thottapalayam vi-
rus 
TPMV Suncus murinus India ? ? 
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Nevertheless, phylogenetic analyses revealed inter- and intra-strain-dependent variabilities. 
Viruses in general have several possibilities to use genetic variations for increasing their “fit-
ness”, for example by genetic drift or genetic shift. For hantaviruses, one possibility of genetic 
variation is given by apparently impaired or absent proof reading activity of the viral RNA 
polymerase (Plyusnin et al., 1996; Choi et al., 2008; Ramsden et al., 2008). Furthermore, re-
assortment processes can be responsible for changes in the genetic background of hantavi-
ruses (Li et al., 1995). Interestingly, the exchange of genomic segments is not distributed 
normally for all three segments; apparently, M seems to undergo reassortment with higher 
probability whereas S and L reassort primilary together (Rizvanov et al., 2004; Rodriguez et 
al., 1998; Klempa et al., 2005) (Kirsanovs, unpublished data). 
1.1.5 Transmission, clinical features and epidemiology 
Hantaviruses establish persistent infections in their reservoir hosts without any apparent dis-
ease (Botten et al., 2000; Hutchinson et al., 1998; Tkachenko and Lee, 1991; Yanagihara et 
al., 1985). They are transmitted to humans through aerosols containing viruses derived from 
rodent feces, urine, or saliva (Tsai, 1987). Thus the respiratory tract represents the primary 
replication site (McCaughey and Hart, 2000; Schonrich et al., 2008). However, virus trans-
mission can also occur by rodent bites (Gonzalez et al., 1984; Hart and Bennett, 1999). Hu-
man-to-human transmissions usually do not occur and were only observed in individual cases 
for Andes virus (ANDV) (Padula et al., 1998; Wells et al., 1997). 
Hantaviruses show similar tropisms in rodents and humans. The vascular endothelium is pos-
tulated as the main target tissue in hantavirus infections since viral antigen could be detected 
in endothelial cells derived from lung, kidney, heart and lymphoid organs (Green et al., 1998; 
Zaki et al., 1995). Typical human disease patterns after infection with Old and New World 
hantaviruses are hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopul-
monary syndrome (HCPS), respectively.  
HFRS is characterised by fever, abdominal pain and drop in blood pressure and can even lead 
to vascular hemorrhage, kidney dysfunction, cardiogenic shock and renal failure which is 
mainly caused by HTNV, SEOV and DOBV (Cosgriff and Lewis, 1991; Kanerva et al., 1998; 
Tkachenko and Lee, 1991). The number of reported cases amounts to 100,000 per year with 
case fatality rates between 1 to 15% depending on the responsible hantavirus strain. In 
Europe, PUUV seems to be the major pathogenic hantavirus since it is responsible for ap-
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proximately 6,000 annual cases of mild HFRS, also called nephropathia epidemica (NE), with 
fatality rates of 0.1% (Vapalahti et al., 2003).  
HCPS is found in North and South America and caused by SNV and ANDV, respectively. The 
disease pattern is characterised by vascular hemorrhage, pulmonary edema and respiratory 
distress and can – in severe cases – lead to myocardial dysfunction; the case fatality rate 
reaches up to 50% (Khan and Young, 2001; Schmaljohn and Hjelle, 1997). However, clinical 
features of both disease patterns are not mutually exclusive and can also occur occasionally 
during infection with the respective other type of virus. Additionally, thrompocytopenia, pro-
teinuria and leukocytosis may arise during both infection courses (Kanerva et al., 1998; Zaki 
et al., 1995). Some hantaviruses are constituted as non-pathogenic, but their pathogenic poten-
tial is not completely clear yet; for example, Tula virus (TULV) and Prospect Hill virus (PHV) 
seem to be non-pathogenic, but recently, a HFRS case after infection with TULV has been 
reported (Klempa et al., 2003). 
1.2 Experimental systems for hantaviral studies in cell culture and animal models 
All procedures involving pathogenic hantaviruses have to be carried out under biosafety level 
3 (BSL3) conditions. Hantaviruses infect different cell types, for example A549 cells (human 
lung epithelial cells), VeroE6 cells (green monkey epithelial kidney cells), primary endothelial 
cells, monocytes, macrophages and megacaryocytes. However, inspite of strong dysregulation 
of endothelial cell function and an intense adaptive immune response in case of some patho-
genic hantaviruses in vivo, neither pathogenic nor non-pathogenic hantaviruses seem to cause 
a cytopathic effect in permissive cells, and endothelial cell permeability is not increased in 
vitro (Hjelle and Yates, 2001; Kitamura et al., 1983; Nagai et al., 1985; Pensiero et al., 1992; 
Sundstrom et al., 2001; Yanagihara and Silverman, 1990).  
Furthermore, the absence of appropriate animal models hampers in vivo-analyses of hantavi-
ruses. Therefore, it is quite difficult to investigate how hantaviruses increase endothelial per-
meability and thereby cause disease (Kanerva et al., 1998), indicating cytokines or similar 
molecules released from infected cells as factors for hantavirus pathogenesis. 
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1.3 Immunology 
1.3.1 Innate immunity 
1.3.1.1 Pattern recognition receptors 
The innate immune system provides a first line of defence against pathogens. In contrast to 
the specific adaptive immune system that comprises cellular (T cells) and humoral (B cells) 
mechanisms, the innate immune system senses broad spectra of pathogens with special char-
acteristic structural features, so-called pathogen-associated molecular patterns (PAMPs).  
The detection takes place through pattern recognition receptors (PRRs). There are two main 
receptor families involved in virus detection: Toll-like receptors (TLRs) and RIG-I-like recep-
tors (RLRs). TLRs are membrane-spanning non-catalytic molecules which contain a subclass 
that recognises for example RNA and DNA patterns derived from pathogens including bacte-
ria, viruses, parasites and fungi (Akira and Takeda, 2004; Janeway, Jr. and Medzhitov, 2002), 
whereas RLRs do not rely on membranes and are located in the cytoplasm of the cell. Both 
families induce signalling pathways after binding of PAMPs that for example merge in dimer-
isation of the transcription factor IRF3, followed by transport into the nucleus and transcrip-
tion of type I interferons (IFN). 
CARD CARD
CARDs
925 AA 
repressor domain helicase domain with
conserved motifs
CARD
1025 AA 
925 AA 
RIG-I
MDA5
 
Figure 4. Domains of RIG-I and MDA5: Structure of the RLRs RIG-I and MDA5 with conserved motifs 
within the helicase domain depicted dark red or dark orange, respectively (Saito et al., 2007) 
This study particularly focuses on RLRs and their influence on IFN-β activation by hantavi-
ruses. Retinoic acid inducible gene (RIG-I, also known as DDX58) and melanoma differentia-
tion-associated gene 5 (MDA5, also known as IFIH1) belong to the family of DexD/H box 
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helicases, both comprising two caspase recruitment domains (CARDs) located at the N-
terminus (Figure 4). After binding of PAMPs with RIG-I, homodimerisation and a conforma-
tional shift occur. The CARDs are then free to interact with the adaptor molecule anchored in 
the outer mitochondrial membrane, IFN-β promotor stimulator (IPS-1) (also called mitochon-
drial antiviral signalling (MAVS; KIAA1271), virus-induced signalling adaptor (VISA), or 
CARD adaptor inducing IFN-β (CARDIF) thereby activating downstream signalling proc-
esses through Fas-associated protein with Death Domain (FADD) and other proteins like the 
Iκ-β kinase family members TBK-1, IKKi and IKKα/β that lead to activation of the transcrip-
tion factors IRF3 and NFκB (Lin et al., 1998; Sato et al., 1998; Weaver et al., 1998; Li et al., 
1999) (Figure 5).  
MAVS
FADD
RIP1
TRAF6
TAB1 TAB2
TAK1
IKKαβIKKi
IRF3 NFκBIκB
TNFα etc.IFNβ
TRAF2
CARD
RIG-I CARD CARD
TBK1
RIG-I CARD CARD
TRAF3
CARD CARDMDA5
5‘3p
 
Figure 5. Signal transduction pathway of RIG-I and MDA5 
IRF3 is phophorylated and then homodimerises for translocation into the nucleus (Akira and 
Takeda, 2004; Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005; Yo-
neyama et al., 2004). Coordinated binding of transcription factors leads to an induction of 
IFN-β expression, thus creating an antiviral status in the host. In addition, the RIG-I-
associated signal transduction triggers the expression of other cytokines like tumor necrosis 
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factor α (TNF-α) through NFκB activation, thereby activating natural killer (NK) cells, den-
dritic cells (DCs) and macrophages (Balachandran and Barber, 2004; Du and Maniatis, 1992; 
Kato et al., 2005; Maniatis et al., 1998; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005; 
Yoneyama et al., 2004). 
A third member of RLRs is LPG2, which is ubiquitously expressed like RIG-I and MDA5, 
but lacks the CARDs. It acts as a negative regulator of RIG-I when overexpressed in cells, 
but, on the other hand, features activating abilities when building heterodimers with RIG-I or 
MDA5 and their ligands (Komuro and Horvath, 2006; Saito and Gale, Jr., 2008b; Venkatara-
man et al., 2007; Yoneyama et al., 2005) (Figure 7).  
1.3.1.2 Ligands of RLRs 
The main PAMP recognised by RIG-I is single-stranded RNA (ssRNA) with a triphosphate at 
its 5’ end, whereas MDA5 detects double-stranded RNA (dsRNA) (Alexopoulou et al., 2001; 
Hornung et al., 2006; Pichlmair et al., 2006). However, RIG-I is also able to bind RNA inde-
pendent of 5’-triphosphates. MDA5 prefers longer dsRNAs of approximately 2 kbp whereas 
RIG-I shows only binding activity for short dsRNA of probably at least 70 bp to 1 kbp or 
short polyI:C (Kato et al., 2006; Kato et al., 2008). Furthermore, RIG-I has also been found to 
recognise homopolyuridine or homopolyadenine motifs for example within the 3’ non-
translated region of the hepatitis C virus (HCV) (Saito et al., 2008). For this kind of ligands, 
the 5’-triphosphate is necessary for triggering immune response, but not sufficient. In general, 
binding mainly relies on the ribonucleotide composition, length and structure (Saito and Gale, 
Jr., 2008a). In contrast, cellular RNAs, transcribed in the nucleus, are processed and modified, 
therefore not triggering innate immune mechanisms (Hornung et al., 2006; Kariko et al., 
2005; Pichlmair et al., 2006). 
1.3.1.3 Viruses and RLRs 
Many viruses provide appropriate PAMPs to RIG-I during their life cycle. Most of them are 
RNA viruses as shown in Figure 6. However, activation of RIG-I signalling has also been 
shown for Epstein-Barr virus (EBV), a DNA virus (Samanta et al., 2006). For wide-spread 
DNA viruses like for example Herpes simplex virus (HSV), no interaction with RLRs could 
be detected yet, although they are known to generate dsRNA during replication (Weber et al., 
2006). 
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MDA5 is known to be important for the detection of viruses belonging to the family of Picor-
naviridae (Gitlin et al., 2006). The specific structural component that is recognised by MDA5 
has not been defined yet. 
RIG-I CARD CARD
RIG-I CARD CARD CARDCARD MDA5
MAVSCARD MAVS CARD
ssRNA (-): Arenaviridae: LASV  Bunyaviridae: RVFV 
Filoviridae: EBOV  Orthomyxoviridae: FLUAV, FLUBV 
Paramyxoviridae: MV, NDV, NiV, RSV, SeV 
Rhabdoviridae: RV, VSV 
ssRNA (+): Picornaviridae: EMCV                                                
Flaviviridae: DV, WNV
poly (I:C)
ssRNA (+): 
Flaviviridae: 
DV, HCV, 
JEV, WNV
in vitro-transcribed RNA
poly (I:C)
DNA: 
Herpesviridae: 
EBV
 
Figure 6. Ligands of RIG-I and MDA5: Artificial ligands and viruses inducing signalling cascades through 
RIG-I and MDA5, sorted by virus families and genome classifications (see list for abbreviations) (Loo et al., 
2008). 
Furthermore, some viral immune evasion mechanisms targeting cytoplasmic sensors have 
been detected. The V proteins of the familiy Paramyxoviridae, for example, have been shown 
to counteract MDA5, and NS3/4A protease of HCV disrupts RIG-I signalling by cleaving 
MAVS off the mitochondria (Kaukinen et al., 2006). Recently, different hantaviral G proteins 
were found to inhibit RIG-I signalling as well. More precisely, the G1 cytoplasmic tail of New 
York virus (NYV) – but not G1 derived from PHV - blocks RIG-I signalling upstream of 
IRF3 in human endothelial cells by interaction with the TBK1-TRAF3 complex, resulting in 
inhibited transcription from IFN-β promotors and ISREs (Figure 7) (Alff et al., 2006; Spiro-
poulou et al., 2007).  
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Figure 7. Viral evasion mechanisms counteracting signal transduction of RLRs: Viruses und their particular 
proteins interfering with RIG-I and MDA5 signalling are depicted in the same colour as the respective molecule 
of the the signaltransduction pathway.  
1.3.2 Type I interferon 
According to their amino acid sequence, interferons are grouped in three classes: Type I IFN, 
comprising IFN-α, IFN-β, IFN-ω, Type II represented by IFN-γ and Type III interferon with 
IFN-λ. IFN-α, belonging to a multi-gene family, is produced by monocytes and macrophages, 
lymphoblastoid cells, fibroblasts, and some other cell types, whereas IFN-β, encoded by only 
one gene, is mainly synthesised by fibroblasts, epithelial and endothelial cells (Roberts et al., 
1998).  
Type I IFNs are of crucial importance for the antiviral response, and they are produced consti-
tutively in low amounts (Seth et al., 2006; Taniguchi and Takaoka, 2001). They link innate 
and adaptive immunity; for example, they modulate the differentiation of plasmacytoid 
(pDCs) and myeloid dendritic cells (mDCs), Th1/CD8+ T cell responses and cross priming 
and enhance the expression of costimulatory factors and major histocompatibility complex 
(MHC) class I molecules on antigen-presenting cells (APCs). Furthermore, they activate NK 
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cells and enhance primary antibody response (Le Bon et al., 2001; Le Bon et al., 2003; Mon-
toya et al., 2002).  
During the sensitisation phase, entering viruses can activate transcription factors, for example 
IRF3, NFκB and AP-1 through different signalling cascades that lead to production of IFN-β 
and other cytokines by coordinated binding to so-called positive regulatory domains (PRD) 
within the IFN-β promotor, thereby forming an “enhanceosome” (Yoneyama et al., 1998; Chu 
et al., 1999). In the late phase, secreted IFN-β binds to IFN-α/β receptors (IFNARs) in an 
autocrine and paracrine manner and initiates a positive feedback loop. IFNARs activate the 
Janus kinases JAK1 and Tyk-2 that in turn phosphorylate signal transducers and activators of 
transcription (STAT1 and STAT2), leading to a heterotrimeric complex with IRF9, called IFN-
stimulated gene factor 3 (ISGF3) (Samuel, 2001). ISGFs bind to IFN-stimulated response 
elements (ISRE) within the genome, resulting in expression of more than 100 IFN-stimulated 
genes (ISGs). ISGs are for example 2’-5’-oligoadenylate synthetase (OAS) and dsRNA-
dependent serin/threonin protein kinase R (PKR), causing degradation of viral RNAs and in-
hibition of viral protein synthesis (Williams, 2002) respectively, or Mx proteins. The latter are 
GTPases known to interfere with the replication of a broad range of RNA viruses by inhibi-
tion of viral replication (Frese et al., 1996).  
1.3.3 Hantaviruses and immunity 
Although hantaviruses do not necessarily induce strong type I IFN responses, IFNs inhibit 
hantavirus replication effectively (Kanerva et al., 1998; Nam et al., 2003; Temonen et al., 
1995). Therefore, hantaviruses counteract innate immunity by blocking signalling pathways 
which lead to IFN expression. The effectiveness of influencing signalling cascades and there-
fore the success of replication and expansion differs between pathogenic and non-pathogenic 
hantaviruses.  
Many ISGs are upregulated after infection of human endothelial as well as human lung 
epithelial cells with hantaviruses (Geimonen et al., 2002; Nam et al., 2003), but hantavirus 
strains differ in terms of impact on cellular gene expression patterns. Microarray studies 
showed high expressions of ISGs early after infection with non-pathogenic PHV, in contrast 
to pathogenic strains like HTNV and NYV that did not elicit immune response-related expres-
sions earlier than 4 days post infection (d p.i.) (Geimonen et al., 2002). However, data about 
interactions of different hantavirus strains with innate immunity are incomplete. 
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Kraus et al. found that HTNV showed an induction of IFN-β in human umbilical vein endo-
thelial cells (HUVECs) while this effect is only marginal for the less pathogenic TULV (Kraus 
et al., 2004). Furthermore, inefficient replication of TULV correlates with early MxA expres-
sion whereas strong replication of pathogenic HTNV goes along with retarded MxA expres-
sion.  
Oelschlegel et al. conclude that MxA is not necessarily responsible for an inhibition of HTNV 
through class I IFN (Oelschlegel et al., 2007), whereas Frese et al. (Frese et al., 1996) showed 
an inhibition of several members of the Bunyaviridae including HTNV by stably transfected 
MxA expressed in Vero cells, congruently to Kanerva et al. who received similar results for 
PUUV and TULV (Kanerva et al., 1996). However, the latter group could not reproduce the 
inhibitory effect ascribed to transfected MxA in cell clones derived from a human leukemic 
monocyte lymphoma cell line (U-937). 
Spiropoulou et al. observed high levels of IFN-β induced by PHV in human pulmonary mi-
crovascular endothelial cells (HMVEC-L), but no induction by ANDV early after infection, 
correlating with IRF3 activation, although both strains were able to downregulate IFN signal-
ling (Spiropoulou et al., 2007). The study by Alff et al. detected strong IFN-β responses early 
after infection of human endothelial cells with PHV, but not with HTNV and NYV (Alff et al., 
2006). 
Furthermore, several groups have investigated whether single hantaviral components interact 
with cellular immune signalling components. As already mentioned above, the cytoplasmic 
tail of the G1 protein of pathogenic NYV but not non-pathogenic PHV blocks RIG-I signal-
ling by disrupting the TBK1-TRAF3 complex and thereby inhibiting transcription from IFN-β 
promotors and ISREs (Alff et al., 2006; Alff et al., 2008; Spiropoulou et al., 2007).  
G proteins from ANDV and PHV were able to downregulate IFN signalling by blocking the 
phosphorylation of STAT1 and STAT2 (Spiropoulou et al., 2007). Additionally, in G1 tails of 
HCPS-inducing hantaviruses, immunoreceptor tyrosine-based activation motifs were found 
that are able to interact with cellular kinases (Geimonen et al., 2003). 
TULV- and HTNV-derived N proteins interact with ubiquitin-like modifier-1 (SUMO-1) 
(Kaukinen et al., 2003; Lee et al., 2003), whereas for PUUV N protein, interaction with an 
apoptosis enhancer, Daxx, has been observed (Li et al., 2002). Another recent finding indi-
cates that the NS proteins of TULV (which, until recently, were undefined) and PUUV could 
be involved in IFN inhibition (Jaaskelainen et al., 2007).  
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1.3.4 Pathogenesis of hantaviruses 
The immune response plays a crucial role for the pathogenesis of hantaviruses, although the 
exact mechanisms correlating with the severity of clinical symptoms caused by different han-
taviral strains have not been elucidated yet. Cells involved in virus detection are immune 
cells, but also endothelial cells that function as main target cells after virus infection. Hantavi-
ruses are also able to infect and to activate immature dendritic cells (DCs) thereby inducing 
cytokine secretion, for example TNF-α and Type I IFN, and upregulating MHC class I as well 
as adhesion molecules (Raftery et al., 2002). 
Expression of vascular endothelial growth factor (VEGF), regulated in activation, normal T 
cells expressed and secreted (RANTES, CCL5) and the 10 kDa IFN-inducible protein (IP-10, 
CXCL10) is increased after infection of HMVEC-Ls with HTNV and SNV (Sundstrom et al., 
2001). RANTES and IP-10 are known attract leucocytes, and IP-10 additionally plays an im-
portant role in the development of a Th1 response, whereas VEGF is a specific enhancer for 
microvascular permeability and can recruit monocytes (Khaiboullina and St Jeor, 2002; Sund-
strom et al., 2001; Gavrilovskaya et al., 2008).  
Activation of macrophages and monocytes triggers cytokine release. Many cytokines can be 
detected in significantly increased levels in human plasma such as IFN-β, IFN-γ, TNF-α, in-
terleukin 2 (IL-2) and IL-6 during the acute phase of infection (Geimonen et al., 2002; Khai-
boullina and St Jeor, 2002; Linderholm et al., 1996; Makela et al., 2004; Peters and Khan, 
2002; Zaki et al., 1995). Furthermore, other biochemically active substances like nitrogen 
oxide and reactive oxygen are induced that may lead to local tissue damage, increased perme-
ability of endothelial cells and possibly disturbed hemostasis (Kanerva et al., 1998). 
In HFRS patients, the early cellular immune response is mainly directed against the N pro-
teins, although epitopes against all structural proteins could be found. Hantaviral N protein is 
highly immunogenic and contains several B-cell as well as T-cell epitopes (Lundkvist et al., 
1995; Van Epps et al., 1999; Van Epps et al., 2002; Vapalahti et al., 1995). During the humoral 
response against hantaviruses, all Ig subclasses are involved (Gott et al., 1997; Vapalahti et 
al., 1995). In later phases, the amount of IgM declines. Meanwhile, levels of IgG directed 
against both hantaviral glycoproteins overbalance (Groen et al., 1992; Kanerva et al., 1998; 
Lundkvist et al., 1993). Antibodies cross-react for many hantavirus species. 
Nevertheless, the relation between adaptive immune response and pathogenesis has not been 
clarified yet. It has been suggested that the hantavirus-induced immunity plays a major role 
leading to microvascular leakage due to virus-specific CTL responses (Van Epps et al., 2002; 
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Schonrich et al., 2008). T lymphocyte activation is mainly triggered by dendritic cells in 
which hantaviruses are also able to replicate. After hantaviral infection, MHC I molecules are 
upregulated in both endothelial cells and DCs (Kraus et al., 2004; Raftery et al., 2002). The 
increased permeability of capillaries is in turn supposed to be the main cause of hantaviral 
symptoms, possibly caused by pathogenic hantaviruses in response to VEGF-directed regula-
tion processes (Vapalahti et al., 2003; Gavrilovskaya et al., 2008).  
It has been shown that in those reservoir hosts in which hantaviral infections remain asymp-
tomatic, the induction of regulatory T cells (Tregs) takes place. Tregs normally function as 
suppressor of immune response thereby contributing to the maintainance of immune homoeo-
stasis. By interfering with the proinflammatory immune response, Tregs possibly limit pa-
thology in the reservoir hosts, but avoid virus cleareance (Easterbrook et al., 2007; Schountz 
et al., 2007), whereas in humans, the opposite could be assumed due to lacking Treg activa-
tion. 
1.4 Aims and scope of this thesis 
The aim of this thesis is to clarify the early steps of hantavirus-directed innate immunity. To 
analyse the influence of RIG-I for hantavirus replication, growth kinetics with pathogenic and 
non-pathogenic hantavirus strains are carried out on wild-type, control and ∆RIG-I cells. Fur-
thermore, a respective hantaviral PAMP should be defined. For this purpose, single hantaviral 
components derived from strains of different pathogenicity are tested in a co-transfection sys-
tem with the PRR of interest and analysed by an IFN-β promoter-related luciferase readout. 
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2 Material 
2.1 Bacteria  
Escherichia coli, XL1-Blue Stratagene (LaJolla, Canada) 
Escherichia coli, One Shot Top10 Invitrogen (Karlsruhe, Germany) 
2.2 Cell lines 
A549 cells human epithelial lung cells ATCC nr.: CCL-185™ 
A549 ∆RIG-I knockdown human epithelial lung cells kindly provided by M. Matthäi, Berlin 
A549 control cells human epithelial lung cells kindly provided by M. Matthäi, Berlin 
293T cells human epithelial kidney cells ATCC nr.: CRL-11268™  
HEK293 cells human epithelial kidney cells  ATCC nr.: CRL-1573™ 
HeLa cells human cervix carcinoma cells ATCC nr.: CCL-2 
Huh7.5 human hepatoma cell line (Binder et al., 2007) 
Huh7.5 RIG-I wt_GUN human hepatoma cell line (Binder et al., 2007) 
Huh7.5 RIG-I ca_GUN human hepatoma cell line (Binder et al., 2007) 
Huh7.5 vector_GUN human hepatoma cell line (Binder et al., 2007) 
Huh7.5 Mda5_GUN human hepatoma cell line kindly provided by M. Binder, Heidelberg 
VeroE6 cells green monkey epithelial kidney cells  ATCC nr.: CRL-1586™ 
2.3 Plasmids 
pcDNA3   Invitrogen (Karlsruhe, Germany) 
pcDNA p125-luc (firefly)  (Yoneyama et al., 1996) 
pcDNA NAK (TBK) Flag (Tojima et al., 2000) 
pcDNA B/NS1 (Dauber et al., 2004) 
pEF-Bos h IKKi Flag (Shimada et al., 1999) 
pEF-Bos-RIG-I Flag (Yoneyama et al., 2004) 
pEF MDA5 myc  (Andrejeva et al., 2004) 
pISRE-Luc plasmid (Firefly) Stratagene (LaJolla, Canada) 
pRL-TK-Luc plasmid (Renilla)  Promega (Mannheim, Germany) 
pSHAG-magic2 Open Biosystems (Huntsville, USA) 
pSHAG-magic2 dRIG Open Biosystems (Huntsville, USA) 
pSCA Stratagene (LaJolla, Canada) 
2.3.1 Hantaviral expression plasmids 
The expression plasmids containing hantaviral N or G proteins were kindly provided by Dr. 
Rainer Ulrich (Berlin/island Riems). 
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2.3.1.1 G protein expression plasmids 
pcDNA DOB saarema G1  
pcDNA DOB slovenia G1  
pcDNA PUU Kazan G1  
pcDNA HTN-GPC  
2.3.1.2 N protein expression plasmids 
pcDNA DOB slovakia N 
pcDNA DOB slovenia N  
pcDNA Hantaan fojnica N  
pcDNA PUU Vranica N  
pcDNA Tula N 
2.4 Hantavirus strains 
A6 reassortant Sina Kirsanovs, Berlin 
A36 reassortant Sina Kirsanovs, Berlin 
DOBV Sk/Aa  (Klempa et al., 2005) 
DOBV Slo/Af  (Avsic-Zupanc et al., 1995) 
HTNV (strain 76-118)  Dr. Åke Lundkvist, Stockholm 
PHV (type-3571)   Dr. Robert Tesh, Galveston 
PUUV  Dr. Åke Lundkvist, Stockholm 
TULV (strain Moravia) Dr. Åke Lundkvist, Stockholm 
2.5 VSV 
VSV was kindly provided by Prof. Dr. Friedemann Weber (Freiburg). 
2.6 Reagents  
Aceton Roth (Karlsruhe, Germany) 
Agarose  VWR (Darmstadt, Germany) 
APS Roth (Karlsruhe, Germany) 
Avicel FMC Biopolymer (Philadelphia, USA) 
Bacto-Agar Gibco/ Invitrogen (Karlsruhe, Germany) 
BME 10x Biochrom AG (Berlin, Germany)  
BSA PAA (Pasching, Austria) 
Bromphenol blue  Serva (Heidelberg, Germany) 
CaCl2  Roth (Karlsruhe, Germany) 
Ciprofloxacin MP Biomedicals (Illkirch, France) 
Coomassie blue Serva (Heidelberg, Germany) 
D-MEM  Biochrom AG (Berlin, Germany) 
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DMSO Roth (Karlsruhe, Germany) 
dNTPs Bioline (Luckenwalde, Germany) 
EDTA AppliChem (Darmstadt, Germany) 
Eisessig Roth (Karlsruhe, Germany) 
Ethanol Roth (Karlsruhe, Germany) 
Ethidiumbromid  Roth (Karlsruhe, Germany) 
FCS  Biochrom AG (Berlin, Germany) 
Formaldehyd Merck (Darmstadt, Germany) 
Formamid Merck (Darmstadt, Germany) 
Glutamin Merck (Darmstadt, Germany) 
Glycerol Roth (Karlsruhe, Germany) 
Glycin  Roth (Karlsruhe, Germany) 
GM-CSF ImmunoTools (Friesoythe, Germany) 
G418-Sulfat Geneticin PAA (Pasching, Austria)  
HBSS Gibco/Invitrogen (Karlsruhe, Germany)  
Hefeextrakt Roth (Karlsruhe, Germany) 
HEPES  Biochrom AG (Berlin, Germany)  
HCl Roth (Karlsruhe, Germany) 
H2SO4  Merck (Darmstadt, Germany) 
Isopropanol  Roth (Karlsruhe, Germany) 
Kanamycin Boehringer-Ingelheim (Ingelheim, Germany) 
KCl Merck (Darmstadt, Germany) 
K2HPO4 Merck (Darmstadt, Germany) 
Lipofectamine 2000 Invitrogen (Karlsruhe, Germany) 
MgCl2 J.T. Baker (Griesheim, Germany) 
MEM Biochrom AG (Berlin, Germany) 
Mercaptoethanol Merck (Darmstadt, Germany) 
Methanol  Roth (Karlsruhe, Germany) 
Milk powder Sufocin (Zeven, Germany) 
MOPS Merck (Darmstadt, Germany) 
N6 primer Amersham Pharmacia Biotech (Piscataway, USA) 
Natriumacetat Merck (Darmstadt, Germany) 
NaCl Roth (Karlsruhe, Germany) 
Na2HPO4  Roth (Karlsruhe, Germany) 
NaN3 Roth (Karlsruhe, Germany) 
NaOH Merck (Darmstadt, Germany) 
Na-Pyruvat Biochrom AG (Berlin, Germany)  
Non-essential amino acids Biochrom AG (Berlin, Germany) 
Nuclease-free water Promega (Mannheim, Germany) 
OptiMEM Gibco/Invitrogen (Karlsruhe, Germany) 
PBS PAA (Pasching, Germany) 
Penicillin/Streptomycin (10000 U/ml) Biochrom AG (Berlin, Germany)  
PolyI:C Sigma-Aldrich (Deisendorf, Germany) 
Propidiumiodid (95-98%)  Sigma-Aldrich (Deisendorf, Germany) 
Protease-Inhibitor-Cocktail  Roche (Mannheim, Germany) 
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Protector RNase inhibitor Roche (Mannheim, Germany) 
Puromycin PAA (Pasching, Germany) 
Rainbow molecular weight marker RPN 800  Amersham Pharmacia Biotech (Piscataway, USA) 
Restore™ Western Blot Stripping Buffer Pierce (Rockford, USA) 
Rnase A Qiagen (Hilden, Germany) 
RNA safe Fermentas (St. Leon-Rot, Germany) 
Rotiphorese-Acrylamid Roth (Karlsruhe, Germany) 
RQ DNase Promega (Mannheim, Germany) 
SDS  Merck (Darmstadt, Germany) 
Sodium bicarbonate Biochrom AG (Berlin, Germany) 
TEMED ICN Biomedicals (Irvine, USA) 
Tetrazyclin Invitrogen (Karlsruhe, Germany) 
TNF-α Roth (Karlsruhe, Germany) 
Tris-Aminomethan Roth (Karlsruhe, Germany) 
Tris-HCl Roth (Karlsruhe, Germany) 
Triton X-100 Roche (Mannheim, Germany) 
Trypanblau Serva (Heidelberg, Germany) 
Trypsin/EDTA Invitrogen (Karlsruhe, Germany) 
Trypsin (TPCK-treated) Sigma-Aldrich (Deisendorf, Germany) 
Tween 20 Merck (Darmstadt, Germany) 
Ultra pure water PAA (Pasching, Germany) 
2.7 Equipment 
Autoclave  
Durchreicheautoklav Getinge (Rastatt, Germany) 
Centrifuges  
Biofuge fresco  Heraeus (Kleinostheim, Germany)  
Centrifuge 5415D  Eppendorf (Hamburg, Germany) 
Megafuge 1.0 Heraeus (Kleinostheim, Germany) 
Multifuge H  Heraeus (Kleinostheim, Germany) 
Optima LE-80K Ultrazentrifuge Beckman Coulter (Krefeld, Germany) 
Sorvall RC24 Superspeed DuPont Instruments (Delaware, USA) 
Sorvall RC-5B DuPont Instruments (Delaware, USA) 
SpeedVac Univapo 150 H UniEquip (Martinsried, Germany) 
Tischzentrifuge Biofuge pico Heraeus (Kleinostheim, Germany) 
Ultrazentrifuge Beckton Dickinson (San José, USA) 
Counting chamber 
Neubauer improved  Marienfeld (Lauda-Königshofen, Germany) 
Cryo container 
CryoContainer Cryo Nalgene Nunc (Wiesbaden, Germany) 
Detection systems 
CCD-Kamera  Bioblock Scientific (Illkirch, France) 
DIANA II-CCD Raytest (Strabenhardt, Germany) 
Electrophoresis and blot systems 
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Elektrophorese-Kammer Mini Trans-Blot Cell  Bio Rad (München, Germany) 
Mini-Protean III  Bio Rad (München, Germany) 
Semi-Dry Blot-Kammer  Owi (Porthmouth, Netherlands) 
FACS  
FACScalibur Becton Dickinson (Heidelberg, Germany) 
Incubators  
Cellstar Heraeus (Kleinostheim, Germany) 
CO2 water-jacketed incubator Nuaire (Plymouth, USA) 
CO2–Inkubator Heraeus (Kleinostheim, Germany) 
Hera Cell 150 Heraeus (Kleinostheim, Germany) 
Laminar flows 
Laminarbox Herasafe Heraeus (Kleinostheim, Germany) 
Sterilbank BSB4A  Gelaire (Sydney, Australia) 
Luminometer  
Berthold Mithras LB940 Berthold (Bad Wildbach, Germany) 
Luminometer LB96V Berthold (Bad Wildbach, Germany) 
Microscopes 
CLSM Leica Microsystems (Wetzlar, Germany) 
Fluoreszenzmikroskop BX60  Olympus (Hamburg, Germany)  
Lichtmikroskop Axiovert 40C  Zeiss (Oberkochen, Germany) 
Mikroskop Axiovert 25 CFL Zeiss (Oberkochen, Germany) 
Mixer  
Innova 4330 New Brunswick (Nürtingen, Germany) 
Polymax 1040 Heidolph (Schwabach, Germany) 
Test tube rotator 34528 Snijders Scientific (Tilburg, Netherlands) 
Vibrax VXR  IKA (Staufen, Germany) 
Vortexer MS1 Minishaker IKA (Staufen, Germany) 
Vortexer Reax 2000 Reax Heidolph (Schwabach, Germany) 
PCR cyclers 
LightCycler® 1.5 system Roche (Mannheim, Germany) 
Thermocycler GeneAmp 9700  Applied Biosystems (Foster, Canada) 
pH meter  
pH-Meter pH 320 WTW (Weilheim, Germany) 
Photometer  
Photometer Ultraspec 3300 pro  Amersham Pharmacia Biotech (Piscataway, USA) 
Spektrophotometer Ultraspec 4000  Amersham Pharmacia Biotech (Piscataway, USA) 
Power supplies 
Powersupply EPS 300  Amersham Pharmacia Biotech (Piscataway, USA) 
Model 200/2.0 Power Supply Bio Rad (München, Germany) 
Pump  
Typ ME2  Vacuubrand (Wertheim, Germany) 
Vakuumpumpe KNF Laboport (New Jersey, USA) 
Refrigerator combinations 
Kombi-Kühlschrank Glasline Liebherr (Ochsenhausen, Germany) 
Liebherr Comfort NoFrost Liebherr (Ochsenhausen, Germany) 
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Liebherr Premium Liebherr (Ochsenhausen, Germany) 
Scales  
Feinwaage  Sartorius (Göttingen, Germany) 
MC1 Laboratory LC 2200P Sartorius (Göttingen, Germany) 
Universalwaage  Sartorius (Göttingen, Germany) 
Thermostats  
Blockheater H250 Roth (Karlsruhe, Germany) 
BT100 Kleinfeld Labortechnik (Gehrden, Germany) 
UBD2 Grant Instruments (Cambridge, UK) 
Transilluminator 
BioDoc Analyze  Biometra (Göttingen, Germany) 
Water bath  
Lauda A100 Lauda (Königshofen, Germany) 
Wasserbad WTE var 3185 Assistent (Sondheim/Rhön, Germany) 
2.8 Buffers and solutions 
2.8.1 Bacterial media  
LB-Medium  
1.5% (w/v) Bacto-Agar 
 
After autoclaving and cool-down to 50 °C, 100 µg/µl of canamycine or ampicillin were added 
and casted into Petri dishes. 
2.8.2 DNA and RNA purification  
2.8.2.1 DEPC water 
0.1% DEPC was ressolved in water, mixed and incubated at RT over night. Sterilisation was 
carried out by autoclavation. 
2.8.2.2 6x DNA sample buffer 
0.1% (w/v) Bromphenol blue 
0.1% (w/v) Xylencyanol 
30% Glycerol 
10 mM  EDTA (pH 8.0) 
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2.8.2.3 1x TAE buffer  
40 mM  Tris acetate  
1 mM EDTA 
pH 8.5  
2.8.2.4 0.5x TBE buffer  
45 mM  Tris 
45 mM  Boric acid 
1 M EDTA 
pH 8.0  
2.8.2.5 10x FA buffer 
200 mM MOPS  
50 mM Natrium acetate 
10 mM EDTA 
pH 7  
2.8.2.6 1x FA buffer 
100 ml 10x FA buffer 
20 ml 37% Formaldehyde 
880 ml DEPC water 
2.8.2.7 5x RNA loading buffer 
32 µl saturated bromphenol solution 
80 µl EDTA (5 mM, pH 8) 
720 µl 37% Formaldehyde 
2 ml glycerole 
3.084 ml formamide 
4 ml 10x FA buffer 
2.8.3 FACS analysis  
2.8.3.1 Blocking solution 
10% FCS 
0.02%  sodium azide 
 PBS 
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2.8.3.2 Fixation solution 
0.37% formaldehyde 
 PBS 
2.8.3.3 Washing solution 
1% FCS 
0.002%  sodium azide 
 PBS 
2.8.4 Focus purification assay 
2.8.4.1 Avicel (2.4%) 
24 g  Avicel 
ad 1 l  aqua bidest 
2.8.4.2 2x BME 
100 ml  10x BME 
10 ml L-Glutamin 
40 ml  NaHCO3 
350 ml ultra pure water 
2.8.5 Hantavirus titration 
2.8.5.1 Agarose overlay 
01:01 1% agarose and BME (with 2% streptomycin and penicillin) 
10% FCS  
2.5% HEPES  
2.8.5.2 Antibody dilution buffer 
0.1% Tween 
5% FCS  
 PBS  
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2.8.5.3 Avicel Overlay 
01:01 1% agarose and BME (with 2% streptomycin and penicillin) 
5% FCS 
2.5% HEPES 
 streptomycin/penicillin 
2.8.5.4 Virus dilution buffer 
25 ml HBSS 
500 µl HEPES 
500 µl streptomycin/penicillin 
250 µl FCS 
2.8.5.5 Washing buffer 
0.15%  Tween 
 PBS 
2.8.6 Immunofluorescence 
2.8.6.1 Fixation solution 
30% methanol 
10% acetic acid 
2.8.6.2 Triton lysis buffer 
20 mM Tris-HCl (pH 7.4) 
137 mM  NaCl 
10% Glycerol 
1% Triton X-100 
2 mM  EDTA 
50 mM  Na-ß-Glycerophosphate 
20 mM  Na-Pyrophosphate 
1 mM  Na3VO4 
1 mM  Pefablock 
2.8.6.3 Mowiol 
2.4 g Mowiol  
6 ml  Glycerol 
7 ml  dH2O 
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• incubate over night 
12 ml Tris (0.2 M), pH 8.5 
• dissolve at 50-60 °C 
• centrifuge for 15 min, 4000 rpm and add 10% (w/v) DABCO   
• storage of aliquots at -20 °C 
2.8.7 SDS-PAGE and Western blot  
2.8.7.1 Ponceau Red 
0.1% Ponceau red  
1% Acetic acid 
2.8.7.2 2x SDS sample buffer 
1.2 ml H2O  
8.3 ml  0.5 M Tris-HCl (pH 6.8) 
6 ml  10% SDS (w/v) 
1.5 ml  Glycerin 
9 mg/ml  Bromphenol blue  
5% ß-Mercaptoethanol 
2.8.7.3 10x SDS electrophoresis buffer 
250 mM Tris  
1.92 M Glycine  
10 g/l SDS  
2.8.7.4 Semidry blotting buffer 
48 mM Tris 
39 mM Glycine 
1.3 mM SDS 
20% Methanol 
2.8.7.5 TBST 
100 mM  Tris-HCl (pH 8.0) 
1.5 M  NaCl 
0.5% Tween 20 
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2.8.7.6 Western blot lysis buffer 
10 mM  Tris-HCl (pH 7.4) 
1 mM  EDTA 
100 mM NaCl 
1 mM  PMSF 
1% Triton X-100 
 
2.9 Antibodies 
2.9.1 Antibodies for immunofluorescence and Western blot 
Table 2: Primary antibodies for immunofluorescence and Western blot 
Dilution Title Manufacturer Species 
IF  WB 
α-β-Actin Acris mouse  1:10000 
α-FLAG (M2) Sigma-Aldrich  mouse 1:600 1:3000 
α-HA Upstate rabbit  1:1000 
α-Hanta N (Razanskiene et al., 2004) rabbit  1:500 
α-Influenza B/NS1 BioGenes rabbit 1:300 1:5000 
α-MAVS Axxora rabbit 1:500 1:1000 
α-myc (9E10) Santa Cruz mouse 1:100 1:1000 
α-RIG-I Axxora rabbit 1:500 1:1000 
α-Tubulin Sigma mouse  1:1000 
 
Table 3: Secondary antibodies for immunofluorescence and Western blot 
Title Manufacturer Target species Species Dilution 
Alexafluor 488 Molecular Probes mouse goat 1:1000 (IF) 
Alexafluor 594  Molecular Probes rabbit goat 1:1000 (IF) 
HRP DAKO mouse rabbit 1:15 000 (WB) 
HRP DAKO rabbit pig 1:15 000 (WB) 
HRP Cell Signalling/NEB rabbit goat 1:10 000 (WB) 
2.9.2 Antibodies for FACS analysis 
Table 4: Antibodies for FACS analysis 
Modification Manufacturer Target species Species Dilution 
CD29 purified Immunotools human mouse 1:50 
CD61 purified Immunotools human mouse 1:50 
IgG1 purified Immunotools human mouse 1:50 
PE IgG/IgM Immunotools mouse goat 1:67 
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2.9.3 Antibodies for focus purification assay 
Table 5: Antibodies/sera for focus purification assay 
Virus strain antibody reference dilution incubation time [d] 
DOBV Slo rabbit (Razanskiene et al., 2004) 1:500 10 
DOBV Sk rabbit (Razanskiene et al., 2004) 1:500 8 
HTNV rabbit (Razanskiene et al., 2004) 1:1000 7 
PHV rabbit strain Malacky (Sibold et al., 1999) 1:1000 8 
PUUV rabbit strain Malacky (Sibold et al., 1999) 1:1000 8 
TULV rabbit strain Malacky (Sibold et al., 1999) 1:1000 10 
A6 rabbit (Razanskiene et al., 2004) 1:500 8 
A36 rabbit (Razanskiene et al., 2004) 1:500 8 
HRP α Rabbit IgG goat Dianova 1:1000  
2.10 Kits 
Albumin Standard Pierce (Rockford, USA) 
Antarctic Phosphatase NEB (Frankfurt, Germany)  
BCS Protein Assay Kit Pierce (Rockford, USA) 
BigDye Terminator 3.1 Kit Applied Biosystems (Foster, Canada) 
Dual-Luciferase Reporter Assay System Promega (Mannheim, Germany) 
EndoFree Plasmid Maxi Kit Qiagen (Hilden, Germany) 
Erase-a-Base® Promega (Mannheim, Germany) 
Expand High Fidelity PCR System Roche (Mannheim, Germany) 
GeneRuler™ DNA Ladder Mix Fermentas (St. Leon-Rot, Germany) 
LightCycler®Fast Start DNA MasterPLUS HybProbe Kit Roche (Mannheim, Germany) 
MagNA Pure LC mRNA isolation Kit I Roche (Mannheim, Germany) 
M-MLV-RT Invitrogen (Karlsruhe, Germany) 
OneStep RT-PCR Kit Qiagen (Hilden, Germany) 
QIAamp MinEluteTM Virus Spin Kit Qiagen (Hilden, Germany) 
QIAamp Viral RNA Mini Kit Qiagen (Hilden, Germany) 
QIAEXII Gel Extraction Kit Qiagen (Hilden, Germany) 
QIAfilter Plasmid Maxi Kit Qiagen (Hilden, Germany) 
Qiagen RNAeasy Mini Kit Qiagen (Hilden, Germany) 
QIAprep Miniprep Kit Qiagen (Hilden, Germany) 
QIAquik PCR Purification Kit Qiagen (Hilden, Germany) 
Qiagen RNeasy Kit Qiagen (Hilden, Germany) 
Superscript III Reverse Transcriptase Invitrogen (Karlsruhe, Germany) 
Super Signal West Dura Extended duration substrate Pierce (Rockford, USA) 
T7 Transcription Kit Fermentas (St. Leon-Rot, Germany) 
TRIZOL Invitrogen (Karlsruhe, Germany) 
Venor®GeM-Mykoplasmen Detektions Kit Minerva Biolabs (Berlin, Germany) 
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2.11 Software 
Adobe Photoshop 7.0 software (Adobe Systems Incorporated, San Jose, CA, USA) 
CellQuest Pro® Becton Dickinson (Heidelberg, Germany) 
MacVector  Apple (Cupertino, USA) 
LightCycler Software 4.05 Roche (Mannheim, Germany) 
Expasy http://www.expasy.org/ 
Multalin http://bioinfo.genopole-toulouse.prd.fr/multalin/multalin.html 
NCBI National Center for Biotechnology Information (NCBI) 
http://www.ncbi.nlm.nih.gov/ 
TINA Raytest (Strabenhardt, Germany) 
2.12 Consumables 
6-, 12-, 24-well plates Becton Dickinson (Heidelberg, Germany) 
Bulbs Ratiolab (Dreieich-Buchschlag, Germany) 
Cell culture flasks T25 Greiner (Frickenhausen, Germany) 
Cell culture flasks T75, T125 Nunc (Wiesbaden, Germany) 
Cell culture dishes Greiner (Frickenhausen, Germany) 
Cell scraper TPP (Trasadingen, Switzerland) 
Eppendorf tubes Eppendorf (Hamburg, Germany) 
FACS tubes VWR (Darmstadt, Germany) 
Falcon tubes TPP (Trasadingen, Switzerland) 
Microscope slides Roth (Karlsruhe, Germany) 
Nitrocellulose membranes Whatman (Dassel, Germany) 
Parafilm Pechiney Plastic Packaging (Chicago, USA) 
Petri dishes TPP (Trasadingen, Switzerland) 
Pipet tips Roth (Karlsruhe, Germany) 
Serological pipets TPP (Trasadingen, Switzerland) 
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3 Methods 
3.1 Molecular biology 
3.1.1 Plasmid preparation 
Single colonies of plated bacteria were picked and grown overnight in appropriate selection 
media at 37 °C on a shaker. Plasmid DNA was processed with QIAprep Miniprep Kit 
QIAfilter, Plasmid Maxi Kit or with EndoFree Plasmid Maxi Kit for transfection according 
to the manufacturer’s instructions. The purified DNA was diluted in an appropriate volume of 
water.  
3.1.2 Transformation 
To insert DNA into bacteria, appropriate amounts of plasmid DNA (20-200 ng) were added to 
competent bacteria and incubated on ice for 30 min. Afterwards, a heat shock was carried out 
at 42 °C for 30 s and 500 µl pre-warmed SOC-medium was added. After 30 min of incubation 
at 37 °C on a shaker, the suspension was plated on petri dishes containing LB-Agar with the 
appropriate antibiotics for selection and incubated at 37 °C overnight. 
3.1.3 Preparation of competent E. coli XL1 blue 
200 ml of LB medium was inoculated with 10 ml of an overnight pre-culture and incubated at 
37 °C on a shaker. When an OD600 of 0.5 was reached, the suspension was centrifuged (10 
min, 4000 rpm) at 37 °C. After resuspending the pellet in 20 ml ice-cold MgCl2 solution (100 
mM) and chilling on ice for 1 h, the centrifugation was repeated. The pellet was resuspended 
in 8 ml ice-cold CaCl2 solution (100 mM) and again chilled on ice for 1 h. After addition of 
glycerol, the competent bacteria were aliquoted and shock frozen in liquid nitrogen. The ali-
quots were stored at -80 °C. 
3.1.4 Agarose gel electrophoresis 
At least 500 ng DNA of the samples were mixed with 6x sample buffer and loaded on agarose 
gels (1%). The DNA was separated with 90-110 V and 300 mA for 30-60 min. Following 
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staining in ethidium bromide solution for 15 min, the DNA bands were visualised on a transil-
luminator. 
3.1.5 Determination of DNA and RNA concentration 
Dissolved DNA and RNA show an absorption maximum at 260 nm that is used for photomet-
ric analyses to determine the sample concentration. For this purpose, the sample was diluted 
and measured. 
A = absorption value  
1 OD = 50 µg/ml 
DNA concentration [µg/µl] = A260 x 50 µg/ml x dilution factor / 1000 
1 OD = 40 µg/ml 
RNA concentration [µg/µl] = A260 x 40 µg/ml x dilution factor / 1000 
3.1.6 Sequencing of hantavirus expression plasmids 
The nucleotide sequence for the entire ORF of each N expression plasmid was confirmed with 
the BigDye DNA sequencing kit. The principle of this kit is based on the classical chain-
termination method by Sanger. The integrities of the constructs were confirmed by DNA cycle 
sequencing by using an ABI Prism 3100 genetic analyzer (Applied Biosystems) and evaluated 
with Sequencing Analyses 3.7 Software.  
PCR program: 
95 °C  1 min 
96 °C 10 s 
55 °C 5 s 
60 °C 4 min 
4 °C  
25 cycles  
 
PCR master mix for one reaction: 
200 ng plasmid 
0.5 µl  T7 primer (20 pM) or Sp6 
1 µl  BigDye 
1.5 µl 5x buffer 
ad 10  Ultra pure water 
 
The histogram data were evaluated with MacVector. 
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3.1.7 Generation of deletion mutants 
To analyse the sections of HTNV N ORF important for activating RIG-I signalling, truncated 
N protein expression plasmids were generated with the Erase-a-Base®-Kit according to the 
manufacturer’s instructions with support of Pritesh Lalwani. Briefly, plasmids were linearised 
by digestion with two different restriction enzymes (XbaI and ApaI) that leave a 4-base 3’ 
overhang resistent to exonuclease activity and a 5’ overhang or blunt end sensitive to exonu-
clease activity. The reaction was stopped according to the designated truncation since there 
are temperature-dependent digestion rates. Samples during exonuclease activity were taken at 
0, 1, 2, 3 and 4 minutes after starting the reaction. After ligation, the plasmids were expanded 
and tested. 
3.1.8 In vitro-transcription and removal of 5’-triphosphates 
In vitro-transcription was carried out with G and N protein expression plasmids after digestion 
with ApaI according to the manufacturer’s instructions (Fermentas). After treatment with 
DNase, the RNA was purified by Phenol/Chloroform extraction or with Qiagen RNAeasy 
Mini Kit, washed with ice-cold 75% ethanol and used immediately for experiments. To test 
the influence of 5’-triphosphates, the transcribed RNAs were digested with phosphatase for 15 
min at 37 °C. Therafter, the samples were purified by Phenol/Chloroform extraction as de-
scribed above. 
3.1.9 RNA gel electrophoresis 
First, the electrophoresis equipment was washed with 0.5% SDS and DEPC water and desin-
fected with ethanol. The gel containing 1.2 g agarose, 10 ml 10x FA buffer and 100 ml DEPC 
water was melted, cooled down to 60 °C in a water bath and mixed with 1.8 ml of 37% for-
maldehyde solution before casting. The gel was equilibrated for 30 min at 65 V. After addition 
of loading buffer to the samples, the samples were incubated for 10 min at 65 °C, chilled on 
ice and run for 1 h at 65 V. Following staining in ethidium bromide solution for 30 min, the 
RNA bands were visualised on a transilluminator. 
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3.2 Cell biological methods 
3.2.1 Cell culture 
VeroE6 cells, African green monkey kidney cells, were maintained in EMEM supplemented 
with 10% FCS, 100 IU penicillin, 100 µg/ml streptomycin and 4.5 mM L-glutamine. A549 
cells, Hela cells, 293T cells, HEK293 cells and Huh7.5 cell lines were grown in DMEM sup-
plemented with 10% FCS, 100 IU penicillin, 100 µg/ml streptomycin and 4.5 mM L-
glutamine. For A549 ∆RIG–I and control cells, 2 µg/ml puromycin was added. For transfected 
Huh7.5 cell lines except for the parental cells, 1 mg/ml G418 was added. Medium and FCS 
were endotoxin-free as certified by the manufacturer.  
To passage confluent monolayers, cells were washed with PBS and treated with Tryp-
sin/EDTA at 37 °C until they detached from the bottom of the flask. Then the cells were re-
suspended in appropriate medium and transferred into a new cell culture flask, plate or dish.  
3.2.2 Freezing cells 
To maintain cell stocks, confluent cells (T75 flask) were trypsinised and washed in PBS. After 
centrifugation (3 min, 800 rpm), they were resuspended in 1 ml FCS with 10% DMSO and 
maintained in a cell culture freezing box at –80 °C over night before transferring them into 
liquid nitrogen. 
3.2.3 Transfection of cells 
Confluent cells were splitted one day before transfection at a ratio of 1:2. DNA and Lipofec-
tamine2000 (2 µl/1 µg DNA) were added to 100 µl Optimem, respectively, mixed and incu-
bated for 5 min at RT. Then the two mixes were combined and incubated for 15 min at RT. 
Meanwhile, the cells were trypsinised and washed with PBS. After centrifugation for 3 min at 
800 rpm, the pellet was resuspended in 10 ml of transfection medium (appropriate medium 
without antibiotics) and seeded into culture dishes or plates. The transfection mix was added 
dropwise. After 6 hours of incubation at 37 °C, the transfection medium was replaced by full 
DMEM. 
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3.3 Virus treatment 
3.3.1 Infection of cells 
Appropriate cells were infected with viral stocks for 1 h at 37 °C as indicated. The virus was 
removed, monolayers were washed with PBS, and cells were maintained in complete media. 
3.3.2 Hantavirus expansion 
Stocks of all hantavirus strains were propagated on VeroE6 cells grown in 25 cm² cell culture 
flasks. Vero cells are not able to produce Type I IFN due to chromosomal deletions (Diaz, 
1988). The cells were inoculated with virus of MOI 0.1 in a total volume of 5 ml medium and 
incubated at 37 °C/5% CO2. After 7 to 10 days (depending on the respective virus strain), the 
cell culture supernatant was transferred to 75 cm² cell culture flasks containing confluent 
VeroE6 cells in a total volume of 20 ml medium. After 7 to 9 days, the cell culture supernatant 
was harvested, centrifuged to remove cell debris, aliquoted and stored at -80 °C. Concentrated 
viral stocks were prepared by pelleting virus from the supernatant of infected cells (4 h, 130 g, 
4 °C). Virus pellets were resuspended in MEM supplemented with 5% FCS and stored at -80 
°C. Virus stocks were free of mycoplasma contamination as tested by PCR. 
3.3.3 Titration of hantaviruses 
Virus titration was carried out as previously described (Heider et al., 2001). In short, VeroE6 
cells were seeded into 6-well plates. When nearly confluent, cell medium was discarded and 
replaced by inoculums of 0.2 ml/well viral stock in ten-fold dilutions. After an incubation 
time of 1 h at 37 °C in a humidified 5% CO2 atmosphere, cells were overlaid with 1.2% 
Avicel 1:1 mixture with BME. The plates were incubated for 7 to 10 days (depending on the 
virus strain) under conditions as indicated above. Thereafter, the overlay was discarded, cells 
were washed twice with PBS supplemented with 0.15% Tween and finally fixed for 10 min 
with 2 ml/well methanol. After the methanol had been removed, the cells were allowed to dry 
and washed again twice. 1 ml of suitable anti-hantaviral serum was added to each well, di-
luted in PBS containing 10% FCS, and incubated for 1 h at 37 °C. After washing five times, 1 
ml of goat anti rabbit IgG conjugated with horseradish peroxidase diluted 1:1000 in PBS with 
10% FCS was added per well, incubated for 1 h at 37 °C, and washed five times. After adding 
0.5 ml/well of chemiluminescence substrate diluted 1:1 in water, the plates were evaluated 
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using a DIANA Chemiluminescence System (Figure 8). Thus, focus forming units (FFUs) 
could be enumerated for titer determination. 
10-1 10-2 10-3
10-4 10-5 NC
 
Figure 8. Chemiluminescent detection of hantaviral FFUs: Titration of HTNV in a 6-well plate in ten-fold 
dilutions 
3.3.4 Focus purification assay 
To obtain genetically homogeneous virus stocks of high purity, a focus purification was car-
ried out (Rang et al., 2006), an indirect method similar to plaque picking normally used for 
expansion of CPE-causing viruses. When nearly confluent, VeroE6 cells seeded into 6-well 
plates were infected with inoculums of 0.2 ml/well viral stock in ten-fold dilutions containing 
HBSS supplemented with 2% HEPES, 2% FCS, 100 IU/ml penicillin and 100 µg/ml strepto-
mycin. After virus adsorption for one hour at 37 °C in a humidified 5% CO2 atmosphere, cells 
were overlaid with 2.5 ml/well of a pre-warmed (42 °C) agarose overlay. The plates were in-
cubated for 7 to 10 days (depending on the virus strain) under conditions as indicated above. 
The overlay was then removed carefully and kept at 4 °C while washing the cells with PBS 
and fixing them with methanol for 10 min. After the methanol had been removed, the cells 
were allowed to dry and washed again twice. 1 ml of suitable anti-hantaviral serum was added 
to each well, diluted in PBS containing 10% FCS, and incubated for 1 h at 37 °C.  
Following five washing cycles, 1 ml of goat anti rabbit IgG conjugated with horseradish per-
oxidase diluted 1:1000 in PBS with 10% FCS was added per well, incubated for 1 h at 37 °C, 
and washed five times. After adding 0.5 ml/well of chemiluminescence substrate diluted 1:1 
in water, the foci could be visualised with the DIANA Chemiluminescence System. A mir-
rored printout of the detected foci with the same size as the original overlay was used to trace 
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the foci on the agarose overlay and to pick them at the respective position (Figure 9). The 
picked material was resuspended in 200 µl medium. Thereafter, the purified focus was used 
for repeated focus purification and virus expansion. 
 
Figure 9. Focus purification procedure (Rang et al., 2006) 
3.3.5 Kinetics 
3.3.5.1 A549 cells 
To examine the physiological importance of RIG-I for hantaviruses, growth kinetics with dif-
ferent hantaviral strains were carried out. A549 wild-type, ∆RIG-I and control cells were gen-
erated and kindly provided by Markus Matthäi (Robert Koch-Institute, Berlin). ∆RIG-I and 
control cells contain the plasmid pSM2c with RIG-I specific and non-target shRNA expres-
sion cassettes (Expression ArrestTM human retroviral shRNAmir individual contructs), oligo ID 
V2HS 199776 and RHS1707, respectively (Open Biosystems).  
All three cell lines were seeded into 6-well plates and infected with HTNV, PHV, TULV, 
DOBV Slo, DOBV Sk (MOI 1) and the reassorted DOBV strains (MOI 0.5). Uninfected cells 
treated with the same medium used for production of virus stocks were maintained as mock 
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control. At certain points in time, 200 µl of the supernatant of each well were taken for later 
titration analyses of virus load. 
3.3.5.2 Huh7.5 cells 
To test the relevance of RIG-I and MDA5 for hantaviral expansion, growth kinetics with 
HTNV, DOBV Slo and DOBV Sk were carried out on different Huh.7.5 cell lines. GUN 
stands for GFP-Ubi-NeoR, the selection cassette of the lentiviral vector. Huh7.5 RIG-
wt_GUN contains the wild-type RIG-I sequence whereas Huh7.5 ca-GUN comprises a consti-
tutive active construct of RIG-I. Huh7.5 vector_GUN is the vector control, and the vector of 
Huh7.5 Mda5_GUN contains the MDA5 ORF. All cell lines were kindly provided by Dr. 
Marco Binder (Institute of Virology, Heidelberg). 
All cell lines were seeded into 6-well plates and infected with HTNV, DOBV Slo and DOBV 
Sk (MOI 1). Uninfected cells were maintained as mock control. At 0 hours post infection (h 
p.i.) and 2, 3, 5 and 7 d p.i., 200 µl of the supernatant of each well were taken for subsequent 
titration analyses of virus load. 
3.3.6 Isolation of total viral RNA 
Total viral RNA from supernatant of infected VeroE6 cells (HTNV, PHV, TULV (MOI 1) or 
mock-infected), was isolated with Trizol RNA isolation method 8 d p.i. according to the 
manufacturer’s instructions (Invitrogen).  
3.3.7 Expansion of VSV 
VeroE6 cells were infected with viral stocks (MOI 0.1) for 1 h at 37 °C as indicated. The virus 
was removed, monolayers were washed with PBS, and cells were maintained in complete me-
dia until virus harvest by collecting the supernatant and freeze/thaw method for remaining 
cells 2 to 4 d p.i.. 
3.3.8 Titration of VSV 
VeroE6 were cultured in 96-well plates until confluence and inoculated with dilutions of 
herpesvirus suspensions from 10-1 to 10-6 in ten-fold increments (8 wells per dilution). The 
final volume was 100 µl/well. The cells were observed for a cytopathic effect (CPE) daily. 
Titers were determined by TCID50.  
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3.4 Protein chemistry 
3.4.1 Dual luciferase assay 
To assess the promotor activity induced by viruses or transfected viral components, dual 
luciferase assays were carried out. The reporter plasmids contain either a luciferase gene 
derived from firefly under control of an IFN-ß (pcDNA p125-luc plasmid) or ISRE promotor 
(pISRE-Luc plasmid) and a constitutive active luciferase gene derived from the jellyfish 
Renilla (pRL-TK-Luc plasmid). For dual luciferase assays, duplicate 12-wells were trans-
fected with 50 ng IFN-β luciferase reporter p125-luc plasmid and 5 ng of the renilla-derived 
pRL-TK-Luc plasmid. To assess the activities of viral components in their interplay with par-
ticular cellular signalling molecules, cells were co-transfected with the indicated amounts of 
expression plasmid (viral protein expression plasmids: 1 µg; cellular molecule expression 
plasmids: 100 ng; RNA: 500 ng). Cells were lysed at 24 h post transfection in 1x passive lysis 
buffer by incubation at 25 °C (15 min) with gentle agitation. Lysates received from transfected 
cells were centrifugated (10 min, 12,000 rpm) and then pipetted into white flat-bottom 96-
well plates (20 µl).  
Dual luciferase assays were performed at least three times in independent experiments and 
duplicates. Empty vector (pcDNA3) was used as negative control, non-structural protein of 
influenza B virus (B/NS1) was used as positive control for inhibition. The firefly luciferase 
activity was normalised with the renilla luciferase activity. Finally, the ratio between each 
respective RIG-I transfected and untransfected sample was calculated to obtain the fold acti-
vation. Efficient transfections were proven by detection of viral antigen, tags or direct detec-
tion of molecules by Western blot. 
3.4.2 Western blot 
The proteins were separated by denaturing SDS-PAGE according to their relative molecular 
mass during discontinuous gel electrophoresis. Then they were blotted on a membrane and 
visualised by indirect antibody detection. Cell extracts were prepared by lysing cells in lysis 
buffer containing protease inhibitor cocktail or taken from luciferase samples resuspended in 
passive lysis buffer provided within the dual luciferase kit (Promega). The samples were cen-
trifuged for 10 min at 12,000 rpm and 4 °C to remove cell debris. Total protein concentrations 
were determined according to the Bradford procedure. Samples were then resuspended in 
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loading buffer containing β-mercaptoethanol and boiled at 95 °C for 5 min for protein denatu-
ration. Proteins in the mass range from 30 to 150 kDa were separated on 10% polyacrylamide 
gels and run at 25 mA/gel. Following electrophoretic separation, proteins were transferred 
onto methylcellulose membranes by semidry blotting method at 75 mA/gel. 
 
Table 6: Gel composition for discontinuous SDS-PAGE 
 resolving gel 10% stacking gel  
30% Acrylamid/Bis (29:1) 3.3 ml 0.83 ml  
1.5 M Tris-HCl, pH 8.8 2.5 ml X  
 X 1.25 ml 0.5 M Tris-HCl, pH 6.8 
10% SDS 100 µl 50 µl  
10% APS 100 µl 50 µl  
TEMED 6 µl 6 µl  
H2O 4 ml 2,8 ml  
 
After verifying the transfer efficiency by staining the membranes with Ponceau red, blots 
were blocked for 1 h at RT in TBST containing 5% milk powder. Blots were incubated for 1 h 
till overnight at 4 °C with specific primary antibodies. Thereafter, they were washed three 
times with TBST, followed by incubation with appropriate secondary antibodies for 1 h at 
room temperature. After five final washing steps, detection was performed by enhanced 
chemiluminescence. 
3.5 Immunological methods 
3.5.1 FACS (fluorescence-activated cell sorting) 
To analyse the receptors on the surface of cells which are important for hantavirus attachment 
and entry, confluent cells were harvested by trypsinisation, centrifuged (4 min, 2,500 rpm) 
and washed with ice-cold washing solution (PBS, 1% FCS, 0.002% sodium azide). Then they 
were incubated with the first antibody for 1 h at 4 °C (1 µl in 50 µl blocking solution (PBS, 
10% FCS, 0.02% sodium azide)). The washing step was repeated twice before staining the 
cells with PE-coupled secondary antibody for 1 h at 4 °C. After two additional washing steps, 
the cells were resuspended in fixation solution (PBS with 0.37% formaldehyde). The meas-
urement was carried out with FACScalibur; for evaluation of obtained results, CellQuest Pro® 
was used. 
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3.5.2 Immunofluorescence 
To observe the localisation of cellular and viral proteins, an immunofluorescence analysis was 
carried out. For this purpose, 1x106 Hela cells were transfected with 2.5 µg RIG-I expression 
plasmid and, if necessary, other expression plasmids (hantaviral N proteins) in 35 mm dishes 
(4 cover slips). 24 hours post transfection, the cells were washed twice with PBS, fixed with 
2.5% formaldehyde and permeabilised with 0.2% Triton in PBS for 10 min, respectively, then 
washed with PBS again three times. Cover slips were incubated with 20 µl of primary anti-
body solution for 1 h at RT. After rinsing the cover slips three times with PBS, secondary an-
tibodies were added and after 1 h rinsed again three times. Then the cover slips were mounted 
on slides using one drop Mowiol and stored at 4 °C until immunofluorescence analysis. 
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4 Results 
4.1 Effects of RIG-I on hantavirus replication  
4.1.1.1 A549 cell lines 
4.1.1.2 Tests of A549 wild-type, RIG-I knockdown and control cells on integrin 
expression and functionality  
To elucidate the physiological role of RIG-I for hantaviruses, virus growth in A549 wild-type, 
A549 RIG-I knockdown (∆RIG-I) and A549 control cells which express a non-target shRNA, 
was investigated. Unfortunately, the A549 control cells could not be involved until the third 
experiment. Therefore, A549 wild-type cells served as control in the first two experiments. 
For all three experiments, different clones of ∆RIG-I cells were used. All cell lines were 
kindly provided by Markus Matthäi (Robert Koch-Institute, Berlin). To assess the amounts of 
RIG-I in the cell lines, Western blot with RIG-I specific antibody was carried out (Figure 10).  
RIG-I
β-Actin
∆RIG-I
A549
control wt
 
Figure 10. RIG-I expression in A549 wild-type, control and ∆RIG-I cells: Western blot of A549 wild-type, 
control and ∆RIG-I cells. Lysates were prepared from T25 flasks with confluent cells in early passages treated 
with type I IFN (500 U/ml). 
As expected, RIG-I was not detectable in the ∆RIG-I cells, whereas a strong expression could 
be shown in the wild-type as well in the control cells. In addition, it has to be mentioned that 
the growth of the ∆RIG-I and the control cells was impaired in comparison to the wild-type 
cells. 
Furthermore, the levels of β3 (CD61) and β1 (CD29) integrins on the surface of the tested 
cells were analysed by FACS to exclude differences in hantaviral growth due to different 
amounts of integrins since these molecules are important for the entry of pathogenic and non-
pathogenic hantaviruses, like for example HTNV and PHV, respectively (Figure 11). 
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(Gavrilovskaya et al., 1999; Gavrilovskaya et al., 1998). Interestingly, the expression of CD61 
was not detectable on the surface of any cell line. CD29, however, was strongly expressed on 
all cell lines. Nevertheless, there are several hints that other receptors are also involved in 
hantavirus attachment and entry (Krautkramer and Zeier, 2008; Kim et al., 2002; Choi et al., 
2008). 
wild-type∆RIG-Icontrol
CD61
A549
435.26 645.89 517.80
CD2929
HEL
PC
340.21
64.49
 
Figure 11. Density of CD29 and CD61 on the surface of A549 wild-type, control and ∆RIG-I cells: Surface 
expression of CD29 (blue) and CD61 (red) on all three cell lines involved into the growth kinetics was measured 
by FACS. The mean fluorescence intensities (MFI) is given above shifted peaks. Filled graphs represent isotype 
controls of respective antibodies. The graph shows the number of cell counts on the Y-axis and the level of emit-
ted fluorescence by labeled cells on the X-Axis. PC means positive control that is represented by unstimulated 
HEL cells (kindly provided by Nina Lütteke), a human megakaryocyte-like cell line, which expresses both CD29 
and CD61 on their surface. These data are representative for the two independent experiments that has been 
carried out.   
As an additional control, VSV growth curves were analysed (Figure 12). As expected, the 
TCID50 values obtained after infection of the ∆RIG-I cells at 1, 3 and 5 d p.i. were up to 1 to 2 
log steps higher than those from the other cell lines. 
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Figure 12. VSV growth curves on A549 cell lines: A549 wild-type, ∆RIG-I and control cells were infected 
with VSV (MOI 1). Supernatant was collected at different points in time after infection and titrated to assess the 
amount of virus. The experiments were carried out twice with two different ∆RIG-I cell clones. 
For the growth kinetics with hantaviruses, supernatants of infected wild-type and ∆RIG-I cells 
were harvested at 1, 2, 3, 4, 5, 6, and 7 d p.i. for the first two experiments. For the third ex-
periment, supernatant from all three cell lines (wild-type, ∆RIG-I knockdown and control 
cells) was collected and analysed after 2, 3, 5 and 7 d p.i.. To assess the production and secre-
tion of progeny of different hantavirus strains in presence and absence of RIG-I, the super-
natants taken at different time points as described above were titrated in duplicates.  
4.1.1.3 HTNV 
In the first experiment HTNV growth curves showed an increasing drift between virus expan-
sion in wild-type and ∆RIG-I cells up to 3 log steps on day 7. In the second experiment, no 
production of virus, neither in the wild-type nor in the ∆RIG-I cells could be detected. The 
titer reduction for all viruses in the second and third experiment could be explained by re-
peated thawing and freezing of the virus supernatants since the titrations had to be carried out 
several times due to problems with cells prepared for the titrations. 
In the third experiment, the HTNV titer peaked at day 3 after infection and then decreased for 
unknown reasons. In general, HTNV did not replicate well in the wild-type cells, although it 
has been shown before that A549 cells can be productively infected with HTNV. Additionally, 
HTNV as one of the more pathogenic strain is more potent to expand in A549 cells than non-
pathogenic strains (Figure 14). As expected, the growth behaviour in the control cells was 
similar to the wild-type A549 cells (Figure 13). 
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Figure 13. HTNV growth curves on A549 cell lines: A549 wild-type, ∆RIG-I and (for the third experiment) 
control cells were infected with HTNV (MOI 1). Supernatant was collected at different points in time after infec-
tion to determine the virus titers. The experiments were carried out with three different ∆RIG-I cell clones.  
4.1.1.4 PHV 
In the supernatant of ∆RIG-I cells infected with non-pathogenic PHV, only few foci could be 
detected, up to 3 log steps at day 6 after infection in comparison to the wild-type cells (Figure 
14). PHV did not produce virions in the wild-type cells. This is not surprising, since non-
pathogenic hantavirus strains replicate less efficiently than pathogenic ones as a result of, for 
example, inadequate immune evasion mechanisms. The third experiment could not be evalu-
ated because of technical problems that will be discussed later. 
  Results 
  45 
0,00E+00
4,00E+03
8,00E+03
1,20E+04
1,60E+04
1 d p.i. 2 d p.i. 3 d p.i. 4 d p.i. 5 d p.i. 6 d p.i. 7 d p.i.
FF
U
/m
l
0,00E+00
3,00E+03
6,00E+03
9,00E+03
1,20E+04
1 d p.i. 2 d p.i. 3 d p.i. 4 d p.i. 5 d p.i. 6 d p.i. 7 d p.i.
FF
U
/m
l
FF
U/
m
l
Ex
pe
rim
e
n
t 1
Ex
pe
rim
e
n
t 2
∆RIG-I
wild-type
 
Figure 14. PHV growth curves on A549 cell lines: A549 wild-type and ∆RIG-I cells were infected with PHV 
(MOI 1). Supernatant was collected at different points in time after infection and titrated. The experiments were 
carried out with three different ∆RIG-I cell clones. The third experiment could not be evaluated due to technical 
problems (data not shown). 
4.1.1.5 TULV 
The kinetics with TULV, which is regarded as non-pathogenic, could only be carried out once 
due to insufficient virus titers of the expanded stocks. Virus levels reached their maximum of 
5x104 FFU/ml at day 7 after infection in the absence of RIG-I whereas in the control as well 
as in the wild-type cells, almost no replication was detected (Figure 15). TULV is known to 
replicate slowly in cell culture compared to other hantavirus strains. Therefore, the late in-
crease in progeny virions is not surprising.  
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Figure 15. TULV growth curve on A549 cell lines: A549 wild-type, ∆RIG-I and control cells were infected 
with TULV (MOI 1). Supernatant was collected at different points in time after infection and titrated.  
4.1.1.6 DOBV Slo 
DOBV Slo, the most pathogenic strain among the Dobrava strains, was the only virus tested 
that showed high replication efficiency in both ∆RIG-I as well as in the wild-type cell line. 
The virus load in the supernatant of ∆RIG-I cells was higher than of the wild-type cells, 
reaching its maximum at day 5 after infection (2.25x105 FFU/ml) for the first experiment 
(Figure 16). Productive infection of the ∆RIG-I cell line, however, could only be proven for 
the first experiment. In the second experiment, few virus progeny was detectable in any su-
pernatant of the infected cells, comparable to the respective experiment with HTNV. Probably, 
similar technical problems can be assumed for these results. In the third experiment, the FFU 
of DOBV Slo peaked at day 3 after infection with 7x104 FFU/ml in the wild-type cells but 
declining rapidly towards the initial values. 
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Figure 16. DOBV Slo growth curves on A549 cell lines: A549 wild-type and ∆RIG-I cells were infected with 
DOBV Slo (MOI 1). Supernatant was collected at different points in time after infection and virus titers were 
determined. The experiments were carried out with three different ∆RIG-I cell clones.  
4.1.1.7 DOBV Sk 
For DOBV Sk, ∆RIG-I cells showed production of virus progeny in all three experiments, 
whereas in the first two experiments, the titers tended towards zero for supernatant from in-
fected wild-type cells (Figure 17). In the third experiment, slight virus replication could also 
be detected in the wild-type cells. Differences were observed in the time-dependent pattern of 
detected virions. In the first experiment, the titer peaked at day 5 after infection with 2x105 
FFU/ml and reached the maximum at day 7 after infection with 4.5x105 FFU/ml, whereas the 
virus levels in both following experiments reached their highest values at day 3 after infection 
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and then declined. However, control cells in the third experiment produced even higher virus 
counts than the ∆RIG-I cells at day 3 after infection. This value could probably be interpreted 
as outlier. 
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Figure 17. DOBV Sk growth curves on A549 cell lines: A549 wild-type and ∆RIG-I cells were infected with 
DOBV Sk (MOI 1). Supernatant was collected at different points in time after infection and titrated. The experi-
ments were carried out with three different ∆RIG-I cell clones. 
4.1.1.8 DOBV reassortants 
To assess the relevance of different segment settings for viral interactions with RIG-I signal-
ling, reassorted virus strains generated by Sina Kirsanovs were involved in the growth studies. 
Briefly, the DOBV mutants A6 and A36 were generated by artificial reassortment processes 
between DOBV Slo and DOBV Sk. A6 contains the S and L segment from DOBV Sk whereas 
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the M segment is derived from DOBV Slo. The segment layout of the reassortant A36 is the 
reverse of A6 (Figure 18). 
 
DOBV Sk DOBV Slo
A36 A6
 
Figure 18. Reassortment scenarios of A6 and A36 with parental strains DOBV Slo and DOBV Sk 
The kinetics could only be carried out twice with the reassorted strains due to low titers of 
virus stocks. Both strains do not replicate as well as their parental strains in VeroE6 which are 
used for virus expansion. Therefore, they could only be involved in the first and the third ex-
periment (Figure 19). 
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Figure 19. A6 growth curves on A549 cell lines: A549 wild-type, ∆RIG-I and control cells were infected with 
the reassortant A6 (MOI 0.5). Supernatant was collected at different points in time after infection and titrated. 
The experiments were carried out with two different ∆RIG-I cell clones. 
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Interestingly, A6 showed a different growth ratio in ∆RIG-I and wild-type cells similar to the 
respective experiment with DOBV Sk (approximately one log difference) as both virus strains 
did not replicate well in the wild-type cell line (Figure 17, Figure 19). In comparison to 
DOBV Sk, A6 replication started earlier and resulted in higher numbers of virus progeny with 
a maximum of 9x106 FFU/ml at day 4 after infection compared to the maximum of DOBV Sk 
with 4.5x105 FFU/ml at day 7 after infection. In the third experiment, A6 also replicated in the 
∆RIG-I cells, but scarcely in wild-type and control cells.  
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Figure 20. A36 growth curves on A549 cell lines: A549 wild-type, ∆RIG-I and control cells were infected with 
the reassortant A36 (MOI 0.5). Supernatant was collected at different points in time after infection and titrated. 
The experiments were carried out with two different ∆RIG-I cell clones. 
A36 was able to replicate in wild-type as well as in ∆RIG-I cells, similar to DOBV Slo 
(Figure 16, Figure 20), with more efficient replication in the ∆RIG-I cells. In the other ex-
periment (experiment 3), almost no replication could be detected. In general, all experiments 
revealed differences in the growth pattern of pathogenic as well as non-pathogenic hantavirus 
strains in wild-type and control cells as compared to ∆RIG-I cells. 
  Results 
  51 
4.1.2 Huh7.5 cell lines 
To investigate the physiological importance of RIG-I for hantavirus replication in an addi-
tional cell line, virus growth in different Huh7.5 cell lines was assessed. Huh7.5 cells are not 
able to express functional RIG-I due to a point mutation in the RIG-I gene (Bartenschlager 
and Pietschmann, 2005; Blight et al., 2002).  
Huh7.5 wild-type cells, Huh7.5 cells stably transfected with a lentiviral vector expressing 
functional RIG-I, constitutive active RIG-I or MDA5 were infected with HTNV, DOBV Slo 
and DOBV Sk. Huh7.5 cells transfected with the empty vector were treated in the same way. 
Supernatants were harvested at distinct points in time. All cell lines were kindly provided by 
Marco Binder (Institute of Virology, Heidelberg). Since the experiment has been carried out 
only once, the results have to be regarded as preliminary data. 
4.1.2.1 HTNV 
 
HTNV growth reached its maximum in Huh7.5 wild-type cells at day 5 p.i. with a titer of 
7.26x106 FFU/ml whereas in Huh7.5 vector control, the virus titer peaked at day 3 p.i. with 
4.2x106 FFU/ml (Figure 21), both immediately declining. All RIG-I- and as well as MDA5-
expressing cells exhibited a strongly reduced virus growth. 
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Figure 21. HTNV growth curves on Huh7.5 cell lines: Huh7.5 cells containing lentiviral vectors expressing 
RIG-I, constitutive active RIG-I (RIGca) or MDA5 and Huh7.5 wild-type (wt) cells were infected with HTNV 
(MOI 1). Supernatant was collected at different points in time after infection and titrated.  
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4.1.2.2 DOBV Slo 
For DOBV Slo, increasing titers over time could be shown in all cell lines except for RIG-I-
expressing Huh7.5 (Figure 22). In general, DOBV Slo proliferated best in Huh7.5 wild-type 
cells. The amount of FFU found in the supernatants of the other cell lines remained similarly 
low although the titers of virus from the Huh7.5 vector control were comparatively higher. 
Surprisingly, the FFU value for the supernatant of MDA5-expressing cells at day 7 p.i. 
exceeded all other values at the same day. 
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Figure 22. DOBV Slo growth curves on Huh7.5 cell lines: Huh7.5 cells containing lentiviral vectors express-
ing RIG-I, constitutive active RIG-I (RIGca) or MDA5 and Huh7.5 wild-type (wt) cells were infected with 
DOBV Slo (MOI 1). Supernatant was collected at different points in time after infection and titrated. 
4.1.2.3 DOBV Sk 
As already shown for DOBV Slo, the DOBV Sk titers from supernatants of all cell lines 
increased over time (Figure 23) except for the constitutive active RIG-I-expressing cell line. 
At day 7 p.i., the supernatant from cells expressing RIG-I showed the highest virus load, even 
higher than the supernatant taken from cell lines lacking RIG-I. The vector control titers 
remained at the level of the respective titers derived from RIG-I-expressing cell lines.  
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Figure 23. DOBV Sk growth curves on Huh7.5 cell lines: Huh7.5 cells containing lentiviral vectors expressing 
RIG-I, constitutive active RIG-I (RIGca) or MDA5 and Huh7.5 wild-type (wt) cells were infected with DOBV 
Sk (MOI 1). Supernatant was collected at different points in time after infection and titrated. 
 
4.2 Impact of single hantaviral components on PRR signalling 
4.2.1 Interaction of viral genomic RNA with cytoplasmic PRRs  
Nucleic acids belong to the main structures recognised by PRRs leading to a type I IFN re-
sponse which is known to be of relevance for innate immunity after hantaviral infection. Han-
taviruses provide RNA in the form of their genome and during their life cycle as m-, v- and 
cRNA. To determine whether they act as PAMP for either RIG-I or MDA5, viral genomic 
RNAs prepared from the supernatant of VeroE6 cells infected with different hantavirus strains 
were investigated. They were co-transfected into 293T cells with luciferase reporters (consti-
tutive active luciferase reporter and IFN-β promotor-controlled luciferase reporter) and PRRs 
in definite amounts. As negative controls, pcDNA3 without N ORF (NC) and supernatant 
prepared from uninfected cells (NC (cell)) were used (Figure 24).  
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Figure 24. Influence of hantaviral genomic RNAs on IFN-β promotor activation through RIG-I: Total RNA 
from the supernatant of infected or uninfected (NC (cell)) VeroE6 cells (MOI 1) was isolated with Trizol RNA 
isolation method 8 d p.i. and transfected into 293T cells together with IFN-β-activated luciferase reporter plas-
mid (firefly), luciferase reporter plasmid (renilla) and RIG-I expression plasmid. As transfection control, an 
additional sample was transfected with empty expression plasmid (NC). 24 hours after transfection, dual 
luciferase assay was carried out. Standard deviations are based on the mean values of three independent experi-
ments with transfections performed in duplicates. Appropriate expression of transfected RIG-I and consistent 
protein load were verified by Western blot. 
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Figure 25. Effect of hantaviral genomic RNAs on IFN-β promotor activation through MDA5: Preparation 
of RNA, transfection, dual luciferase assay and Western blot were carried out as described in Figure 24. Instead 
of RIG-I-expressing plasmid, MDA5 expression plasmid was co-transfected into the cells.  
Only genomic RNAs of HTNV (6.6-fold) and TULV (4.6-fold) virions had a slight, but not 
significant effect on IFN-β promotor activation through RIG-I (Figure 24), whereas none of 
the tested viral RNAs triggered the signalling pathway through MDA5 (Figure 25).  
4.2.2 Induction or inhibition of RIG-I or MDA5 signalling by hantaviral G expressing 
plasmids 
Other investigations have already shown inhibitory effects of hantaviral G1 on RIG-I signal-
ling (Alff et al., 2006; Alff et al., 2008). Based on these findings, several G1 and G protein 
expression plasmids derived from different hantavirus strains were tested in dual luciferase 
assays as described above. Furthermore, a strong inhibitor of RIG-I signalling, the Influenza 
B/NS1 protein, was used as a positive control for inhibition, expecting similar inhibitory ca-
pacity for the tested G proteins.  
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Figure 26. Influence of hantaviral G proteins on IFN-β promotor activation through RIG-I: 293T cells 
were transfected with hantaviral G protein expression plasmids, empty plasmid (NC) or B/NS1 expression plas-
mid and IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid (renilla) and RIG-I 
expression plasmid. 24 hours after transfection, dual luciferase assay was carried out. Standard deviations are 
based on the mean values of three independent experiments with transfections performed in duplicates. Appro-
priate expression of transfected RIG-I and consistent protein load were verified by Western blot. 
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Figure 27. Effect of hantaviral G proteins on IFN-β promotor activation through MDA5: Transfection, dual 
luciferase assay and Western blot were carried out as described in Figure 26. Instead of RIG-I-expressing plas-
mid, MDA5 expression plasmid was co-transfected into the cells. 
In contrast to B/NS1, in our system the investigated G expression plasmids had neither a 
stimulatory nor an inhibitory effect on IFN-β promotor activation through RIG-I (Figure 26) 
or MDA5 (Figure 27).  
4.2.3 RIG-I pathway triggering by expression of hantaviral nucleocapsid ORFs 
To examine whether N expression from different hantaviruses affects signalling by cytoplas-
mic sensor molecules, the influence of N ORF expressing plasmids was studied in dual 
luciferase assays.  
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Figure 28. Induction of IFN-β promotor activity through RIG-I by hantaviral N expression plasmids: 293T 
cells were transfected with hantaviral N protein expression plasmids, empty plasmid (NC) or B/NS1 expression 
plasmid together with IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid (renilla) 
and RIG-I expression plasmid. 24 hours after transfection, dual luciferase assay was carried out. Standard devia-
tions are based on the mean values of three independent experiments with transfections performed in duplicates. 
The probability of significance concerning the fold activation of negative control was determined by Student’s t-
test (* = p ≤ 0.05). Appropriate expression of transfected RIG-I and consistent protein load were verified by 
Western blot. 
Surprisingly, expression of N ORFs derived from pathogenic hantaviruses showed a signifi-
cant deviation from the negative control. HTNV and DOBV Slo, both strains with compara-
tively high virulence and lethality of infected patients, for example, showed significant pro-
motor activations of 34- and 45-fold, respectively, whereas TULV which is normally not 
implicated in cases of illness, stayed in the range of the negative control (12-fold) (Figure 28). 
In contrast, slight, but not significant activation linked to MDA5 could be detected after ex-
pression of DOBV Slo N protein, whereas all other samples had no impact in relation to this 
PRR. TULV even declined below the level of negative control down to inhibition control level 
(Figure 29). 
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Figure 29. Influence of hantaviral N expression plasmids on IFN-β promotor activation through MDA5: 
Transfection, dual luciferase assay and Western blot were carried out as described in Figure 28. Instead of RIG-I 
expressing plasmid, a MDA5 expression plasmid was co-transfected into the cells. 
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4.2.4 Activation of RIG-I by RNAs encoding hantaviral nucleocapsids  
Since the hitherto known PRRs localised cytoplasmically recognise RNA patterns, it was ex-
amined how the N proteins nevertheless were able to trigger IFN promotor activation through 
RIG-I. To prove the hypothesis that the N mRNA is the real activator of RIG-I signalling all N 
protein and – for the sake of completeness – G protein expression plasmids were transcribed 
in vitro and exposed to RIG-I in dual luciferase assays (Figure 31, Figure 32). The integrity of 
generated RNA was tested in a RNA gel (Figure 30). Only N protein expression plasmid-
derived RNAs activated the reporter system, tending to result in similar patterns like the as-
sayed N proteins, again correlating with pathogenicity of the original virus.  
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Figure 30. RNA gel of in vitro-transcribed N ORFs 
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Figure 31. Triggering of IFN-β promotor activity by in vitro-transcribed nucleocapsid RNAs through RIG-
I: RNAs from in vitro-transcribed N protein expression plasmids or empty plasmid (NC) were transfected into 
293T cells together with IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid 
(renilla) and RIG-I. 24 hours after transfection, dual luciferase assay was carried out. Standard deviations refer to 
the mean values of three independent experiments with transfections performed in duplicates. The probability of 
significance concerning the fold activation of negative control was determined by Student’s t-test (* = p ≤ 0.05). 
Appropriate expression of transfected RIG-I and consistent protein load were verified by Western blot. 
Nevertheless, one exception could be observed: DOBV Slo only showed a slight activation 
similar to TULV, although revealing the highest activation level in the previous experimental 
setting.   
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Figure 32. Influence of in vitro-transcribed G RNAs on IFN-β promotor activation through RIG-I: Trans-
fection, dual luciferase assay and Western blot were carried out as described in Figure 31. Instead of in vitro-
transcripts of the N ORFs, in vitro-trancribed G RNAs were transfected into the cells. Standard deviations are 
mean values of two independent experiments with transfections performed in duplicates. 
The G protein-derived RNA, however, induced RIG-I signalling only marginally (Figure 32), 
as already shown for the respective expression plasmids.  
4.2.5 Importance of 5’-triphosphates and inner-sequential structures of in vitro-
transcribed N ORFs on induction of RIG-I signalling 
RIG-I is preferentially activated by single-stranded RNA with 5’-triphosphates that are also 
generated during in vitro-transcription. However, RIG-I is also is able to bind to other RNA 
types depending on length, nucleoside motifs and secondary structures (Kato et al., 2006; Ka-
to et al., 2008; Saito et al., 2008). Since the gradual differences in strain-dependent luciferase 
activation could not be explained only by considering the 5’-triphosphates, the importance of 
the 5’-triphosphates for the observed RIG-I signalling was examined. Therefore, the tran-
scribed RNAs were digested with alkaline shrimp phosphatase to remove the phosphate end-
ings and again co-transfected and analysed in the dual luciferase system (Figure 33). 
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Figure 33. Importance of 5’-triphosphates at nucleocapsid RNAs on IFN-β promotor activation through 
RIG-I: In vitro-transcribed, phosphatase-treated N RNAs or empty plasmid (NC) were transfected into 293T 
cells together with IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid (renilla) and 
RIG-I. 24 hours after transfection, dual luciferase assay was carried out. Standard deviations are based on the 
mean values of three independent experiments with transfections performed in duplicates. The probability of 
significance concerning the fold activation of negative control was determined by Student’s t-test (* = p ≤ 0.05). 
Appropriate expression of transfected RIG-I and consistent protein load were approved by Western blot. 
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Again, differences of the activation pattern could be observed despite of lacking 5’-
triphosphates. However, the activation level was in each case lower than in the previous ex-
perimental setting, and the signalling strength of HTNV (16-fold) and DOBV Slo (2-fold) 
decreased and declined even under the level of PUUV (21-fold).  
4.2.6 Altered levels of RIG-I activation by 3’ truncated N ORF mutants 
In general, there are no obvious sequence homologies of the tested N expression plasmids to 
allow for a conclusion concerning a stimulatory or inhibitory motif. However, to assess the 
questions whether and which parts of the N protein itself or its RNA are responsible for induc-
tion of RIG-I signalling, deletion mutants of HTNV N protein expression plasmid were gen-
erated in cooperation with Pritesh Lalwani using the exonuclease approach. Three candidate 
plasmids with truncations of different length at their 3’ ends were tested in a DNA gel, West-
ern blot and dual luciferase assay (Figure 34).  
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Figure 34. Impact of 3’ deletion in HTNV N ORF on IFN-β promotor activation through RIG-I: HTNV N 
expression plasmid and expression plasmids with 3’ truncated ORFs as well as empty plasmid (NC) were trans-
fected into 293T cells together with IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter 
plasmid (renilla) and RIG-I. 24 hours after transfection, dual luciferase assay has been carried out. Standard 
deviations are based on the mean values of three independent experiments with transfections performed in dupli-
cates. The probability of significance concerning the fold activation of negative control was determined by Stu-
dent’s t-test (* = p ≤ 0.05). Appropriate expression of transfected RIG-I, N proteins and consistent protein load 
were approved by Western blot (B). Furthermore, the undigested plasmids were visualised in a DNA gel (C). 
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The deletion mutant ∆H1 with the longest truncation showed a strongly reduced activation of 
RIG-I signalling in comparison to the untruncated N protein and remained even below the 
level of the negative control. In contrast, the deletion mutant ∆H3 with a short truncation in-
duced levels of luciferase activity similar to the untruncated protein of HTNV despite of its 
weak espression. Although ∆H2 showed a strange band-pattern in the DNA gel and no expres-
sion in the Western blot, it was carried through the experiments as additional control and 
stayed on NC level. 
4.2.7 Analyses of downstream activation of RIG-I signalling pathway by hantaviral N 
ORF expression 
To examine further components involved in signalling downstream of RIG-I and MDA5, the 
pathway was analysed with all hantaviral N expression plasmids in relation to TBK1 and 
IKKi. The experimental settings were the same as described in the previous sub-chapters, the 
only difference was the exchange of RIG-I as overexpressed molecule with TBK1 (Figure 35) 
or IKKi (Figure 36).  
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Figure 35. Influence of hantaviral N expression plasmids on IFN-β promotor activation through TBK1: 
293T cells were transfected with hantaviral N protein expression plasmids, empty plasmid (NC) or B/NS1 ex-
pression plasmid together with IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid 
(renilla) and TBK1 expression plasmid. 24 hours after transfection, dual luciferase assay was carried out. Stan-
dard deviations are based on the mean values of two independent experiments with transfections performed in 
duplicates. Appropriate expression of transfected TBK1 and consistent protein load were verified by Western 
blot. 
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Figure 36. Effect of hantaviral N expression plasmids on IFN-β promotor activation through IKKi: 293T 
cells were transfected with hantaviral N protein expression plasmids, empty plasmid (NC), B/NS1 expression 
plasmid, IFN-β-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid (renilla) and IKKi 
expression plasmid. 24 hours after transfection, dual luciferase assay was carried out. Standard deviations are 
based on the mean values of three independent experiments with transfections performed in duplicates. Appro-
priate expression of transfected IKKi and consistent protein load were verified by Western blot. 
Although background activation levels were higher compared to the previous experiments,  
the gradually increasing activation depending on pathogenicity of the respective strain resem-
bled those of the previous experiments by trend, with exception of PUUV that remained on or 
below the level of the negative control (110-fold for TBK1 (Figure 35) and 70-fold for IKKi 
(Figure 36)). TULV (1-fold for TBK1 and 11.6-fold for IKKi) even declined below the of 
B/NS1 activation level (8.5-fold for TBK1 and 29.3–fold for IKKi) (Figure 36). For TBK1, 
DOBV Slo again showed the highest activation with nearly 692.5-fold (Figure 35). For IKKi, 
HTNV headed the activation level with 1378.7-fold, whereas DOBV Slo only reached 946.6-
fold activation (Figure 36).  
To test the protein expression of the transfected plasmids, Western blots were carried out for 
each experiment. However, in all experiments, each transfected hantaviral expression plasmid 
seemed to interfere strongly with TBK1 expression for unknown reasons (Figure 35, Western 
blot). Interestingly, IKKi expression tested in Western blots was impaired by PUUV and 
TULV N, respectively (Figure 36, Western blot). 
4.2.8 Influences of hantaviral N expression on IFN feedback loop through RIG-I 
Virus-induced IFN expression is enhanced by a positive feedback loop through the JAK-STAT 
signalling pathway resulting in transcriptional activation of ISREs. To assess the downstream 
activation levels induced through RIG-I, all N expression plasmids were co-transfected with 
an ISRE-controlled luciferase reporter, transfection control and RIG-I expression plasmid 
(Figure 37). 
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Figure 37. Influence of hantaviral N expression plasmids on ISRE-promotor activation through RIG-I: 
293T cells were transfected with hantaviral N protein expression plasmids, empty plasmid (NC) or B/NS1 ex-
pression plasmid together with ISRE-activated luciferase reporter plasmid (firefly), luciferase reporter plasmid 
(renilla) and RIG-I expression plasmid. 24 hours after transfection, dual luciferase assay was carried out. Stan-
dard deviations are based on the mean values of two independent experiments with transfections performed in 
duplicates. Appropriate expression of transfected RIG-I and consistent protein load were verified by Western 
blot. 
Interestingly, ISRE activation through RIG-I signalling by N expression was not detectable. 
The activation levels of all tested N expression plasmids remained in range of the negative 
control, those of TULV and PUUV even declined below.  
4.3 Influence on RIG-I localisation by HTNV N expression plasmid  
N ORF expression leads to IFN-β promotor activation and the putative activating agent is the 
N ORF-derived RNA according to the results of this study. However, it cannot be excluded 
that the N proteins also play a role for a way of RIG-I signalling which is unkown yet. To ex-
amine possible sterical interactions between RIG-I and the hantaviral N proteins as well as 
their spacial distribution, HeLa cells were transfected with RIG-I and N protein expression 
plasmids. One day after transfection, the cells were stained with antibodies specifically bind-
ing to RIG-I and hantaviral N protein and prepared for confocal microscopy. As controls, un-
infected cells were co-transfected with RIG-I and empty expression plasmid. Additionally, 
they were stained with antibody against ubiquitious MAVS instead of N protein. 
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Figure 38. Altered localisation of RIG-I in presence of hantaviral N proteins: HeLa cells were co-transfected 
with RIG-I and N protein expression plasmids (HTNV, TULV) or empty vector as mock control. 24 hours after 
transfection, the cells were harvested and stained against RIG-I (green) and hantaviral N protein (red) or against 
MAVS (red) for the control cells and analysed with confocal immunofluorescence microscopy.  
In all samples, cytoplasmic localisation of RIG-I and hantaviral N protein could be detected. 
For cells expressing HTNV N protein, RIG-I seemed to be distributed homogeneously 
whereas in TULV N protein containing as well as in the control cells, RIG-I was localised 
more granularly in the cytoplasm. Co-localisation of N protein with RIG-I could not be ob-
served (Figure 38). 
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5 Discussion 
5.1 Physiological role of RIG-I for restriction of hantavirus replication 
In this thesis, the interplay between hantaviruses and cytoplasmically localised PRRs was 
analysed. Although type I IFN undoubtedly plays an important role for cellular defence to-
wards hantaviruses (Kraus et al., 2004; Pensiero et al., 1992), the details of hantavirus-related 
type I IFN induction still remain unclear. Since hantaviruses replicate in the cellular cyto-
plasm thereby revealing putative PAMPs, cytoplasmic PRRs seem to be likely molecules for 
hantavirus detection. Moreover, an evasion mechanism mediated by the cytoplasmic tail of 
hantavirus G1 protein targeting the RIG-I signalling pathway was revealed recently (Alff et 
al., 2006; Alff et al., 2008; Spiropoulou et al., 2007).   
RIG-I and MDA5 stand at the beginning of a cascade that involves several transcription fac-
tors merging in expression of IFN. They are more widespread PRRs than for example TLRs 
that are mainly expressed by macrophages and DCs (Kadowaki et al., 2001). For many RNA 
viruses, their involvement as sensor molecules has already been shown. 
To assess their relevance for hantaviruses, the growth of pathogenic (Figure 13, Figure 16) 
and non-pathogenic (Figure 14, Figure 15) strains in A549 cells lacking RIG-I expression as 
compared to the respective wild-type cell line was examined. In addition to original Murinae- 
and Arvicolinae-associated virus strains, reassorted virus strains generated from DOBV Slo 
and DOBV Sk as parental strains (unpublished data of Sina Kirsanovs) were involved in the 
growth studies (Figure 19, Figure 20). The experiment was carried out three times, under 
utilisation of three different knockdown clones. For the third experimental setting, a cell line 
containing the lentiviral vector with a control shRNA instead of RIG-I-directed shRNA was 
added as additional control. The validity of the experimental system was verified by carrying 
out growth kinetics with VSV, a virus for which RIG-I is known to be the relevant PRR. As 
expected, VSV replicated better in the ∆RIG-I cells whereas the growth was limited in wild-
type as well as in the control cell line (Figure 12). Therefore, off-target effects by the vector 
can probably be excluded for our read-out since VSV growth behaviour was similar in wild-
type and control cells. In addition, clonal variability of the ∆RIG-I cell clones is not very 
likely as only slight variations for VSV titers were observed (Figure 12). 
For hantaviruses, the comparability of the three single experiments is hampered for several 
reasons. Firstly, different clones of the ∆RIG-I cells were employed although no distinctive 
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features could be noticed in growth kinetics with VSV or FACS analyses of surface mole-
cules. Secondly, the cells provided by the cell culture lab for titration of the supernatant of 
infected cells were of varying quality. In the first experiment, logistical problems did not oc-
cur so that the data could be evaluated after the first titrations and the supernatants had not to 
be frozen and thawn repeatedly.  
In general, the control cells involved in the third experiment showed similar curves for virus 
progeny as the wild-type cell line except for DOBV Sk where one value even exceeded the 
respective value of the ∆RIG-I cells after infection, which most likely can be taken as an out-
lier (Figure 17). Interestingly, the reassortant A6 containing the M segment of DOBV Slo and 
the S and L segments of DOBV Sk replicated best in the ∆RIG-I cells compared to all other 
viruses. In addition, A6 showed growth differences in ∆RIG-I and wild-type cells similar to 
DOBV Sk, approximately 1 to 2 logs (Figure 17, Figure 19, first experiments, respectively). 
A36 and DOBV Slo, in turn, which both were able to replicate in ∆RIG-I as well as in wild-
type cells, also showed similar growth differences up to only a half log (Figure 16, Figure 20, 
first experiment, respectively). This hints at a special relevance of the S and/or the L segment 
for viral expansion.  
To exclude growth differences based on differential integrin expression on the cell lines, the 
density of CD29 and CD61, regarded as important for the entry of non-pathogenic and patho-
genic hantaviruses, respectively (Gavrilovskaya et al., 1998; Gavrilovskaya et al., 1999; 
Gavrilovskaya et al., 2002), were measured by FACS analyses (Figure 11). Surprisingly, the 
quantification of integrins revealed that CD61 was not present at all on the cell surface of 
∆RIG-I, wild-type as well as of control cells. This was also observed by other groups 
(Hamada et al., 2001). In contrast, CD29 could be detected on the surfaces of all three cell 
lines. Nevertheless, productive infection with pathogenic HTNV was observed. These results 
hint at other receptor molecules involved in hantavirus entry (Krautkramer and Zeier, 2008; 
Choi et al., 2008). In general, despite of high differences in virulence, pathogenic and non-
pathogenic hantaviruses could better replicate in the ∆RIG-I cells than in the A549 wild-type 
cell line. 
To confirm the observed effects, a similar kinetic was carried out in another cell line, Huh7.5 
cells that contains a point mutation in the RIG-I gene (Bartenschlager and Pietschmann, 2005; 
Blight et al., 2002). For gain-of-function experiments, the same cell line complemented with a 
RIG-I and a constitutive active RIG-I expressing lentiviral vector or with empty vector and 
MDA5 was infected with HTNV, DOBV Slo and DOBV Sk. Preliminary data show that all 
  Discussion 
  66 
three hantavirus strains proliferate better in cells lacking RIG-I (Figure 21, Figure 22, Figure 
23). The value for cells infected with DOBV Sk at day 7 p.i. is taken as an outlier. Highest 
titers were found in Huh7.5 wild-type cells, slightly reduced titers in supernatants derived 
from the infected Huh7.5 vector control cells. This suggests that the lentiviral vector influ-
ences hantavirus entry and/or replication to some extent. Virus growth in RIG-I and constitu-
tive RIG-I expressing cells was generally low except for cells infected with DOBV Sk RIG as 
described above. Hence, in this experimental setting, it does not seem to be important for vi-
rus proliferation whether RIG-I is constitutively active or initially has to be activated by infec-
tion. The role of MDA5 is not clear yet, since for HTNV and DOBV Sk, the titers remained 
on the level of RIG-I expressing cells whereas for DOBV Slo MDA5, the value of FFU/ml 
even exceeded all other titers at 7 d p.i.. 
In general, there was no clear correlation between virus growth and pathogenicity of the cor-
responding hantavirus strain as we did not find significantly higher replication of pathogenic 
hantaviruses compared to the non-pathogenic strains in the respective cell line. Most of the 
investigated hantavirus strains grew better in cells with impaired RIG-I expression in com-
parison to control cells. Therefore, we can conclude that RIG-I seems to play a role as sensor 
molecule for pathogenic as well as for non-pathogenic hantaviruses in cell culture. However, 
the mechanism and possible influences by other PRRs are not understood yet due to delicate 
balances between viral defence mechanisms and the cellular detection system initiating an 
antiviral response. 
5.2 Interaction of hantaviral components with RIG-I and MDA5 
To define potential hantaviral PAMPs, all available components of several hantaviruses differ-
ing in pathogenicity, epidemiology and reservoir hosts, were examined. Their ability of trig-
gering or blocking innate immune response through cytoplasmic PRRs was investigated. It 
had been assumed that RIG-I and MDA5 are activated mainly by interaction with 5’-
triphosphate single-stranded RNA and double-stranded RNA, respectively. However, the pos-
sibility of a certain redundancy in recognition of different RNA patterns cannot be excluded 
(Imaizumi et al., 2005; Yoneyama et al., 2004). For example, RIG-I could also be activated by 
dsRNA dependent on its length, and a polyuridine motif in the non-coding region of HCV was 
found to play a role for RIG-I induction (Saito et al., 2008). In addition, involvement of both 
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RIG-I und MDA5 in recognition of West nile virus (WNV) (Fredericksen et al., 2008) and of 
dsDNA was observed (Cheng et al., 2007).  
5.2.1 Relevance of genomic RNA as ligand of RIG-I 
Viruses with a negatively orientated RNA genome do not necessarily form detectable double-
stranded RNA structures. Furthermore, neither hantaviral genomes nor the viral mRNAs nor-
mally contain free 5’-triphosphates at their end. The genome is structured as a panhandle 
bound by the viral N protein, thus preventing detection by RIG-I by masking the RNA (Mir 
and Panganiban, 2006). Therefore, it is not surprising that only weak or no activation of RIG-I 
signalling by hantaviral genomic RNAs could be detected (Figure 24), as also observed by 
Habjan et al. (Habjan et al., 2008). 
Although vRNA did not activate the IFN-β promotor through MDA5 either (Figure 25), the 
relative fold activations were much higher than for respective RIG-I samples. This could be 
explained by the fact that MDA5 does not possess a C-terminal repressor domain like RIG-I 
therefore inducing high background activity (Pichlmair et al., 2006; Saito et al., 2007). 
5.2.2 Role of hantaviral glycoproteins in the interplay between hantaviruses and 
cytoplasmic sensor molecules 
The hantaviral G proteins examined in our experimental setting neither triggered nor inhibited 
signalling through MDA5 or RIG-I (Figure 26, Figure 27). In comparison to another inhibitor, 
the Influenza B/NS1 protein (Opitz et al., 2007; Dauber et al., 2004), blocking properties of 
the hantaviral G proteins could hardly be detected. However, it has to be mentioned that no 
challenge for proving or excluding specific inhibition as carried out by other groups was in-
cluded into our experimental setting. In contrast to our findings, it has been shown by Alff et 
al. that G1 protein tails derived from pathogenic hantavirus strains inhibit RIG-signalling after 
transfection of a constitutive active RIG-I deletion mutant, whereas the G1 protein from non-
pathogenic PHV was not able to suppress the signalling cascade (Alff et al., 2006; Alff et al., 
2008).  
Activation of PRR signalling by G proteins could not be observed either. Interestingly, even 
the in vitro-generated G ORF RNA did not result in IFN-β induction through RIG-I (Figure 
32), although it contains 5’-triphosphates. Possibly, the RNA derived from G encoding ORF 
has structural or sequential properties that abrogate the impact of 5’-triphosphates on detec-
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tion by RIG-I. If hantaviral G proteins provide PAMPs, then the respective PRRs are probably 
localised on the surface of the host cell or in the endosomes like for example TLRs which 
could be activated during attachment and entry processes.  
5.2.3 Induction of RIG-I signalling by hantaviral N ORF expressing plasmids  
5.2.3.1 Activation of RIG-I signal transduction by expression of hantaviral N ORFs 
For many viruses, the interplay between PRRs or downstream molecules and a viral protein 
has been discovered. For example, an interaction of RIG-I and NS1 of Influenza viruses was 
recently described (Dauber et al., 2006; Pichlmair et al., 2006). For hantaviruses, similar co-
herences could be assumed as well. A potential candidate for interactions with PRRs is the 
hantaviral N protein. It plays an important role during the life cycle of hantaviruses, function-
ing as an RNA chaperon and recognising the viral genomic panhandle (Alminaite et al., 2006; 
Mir and Panganiban, 2006). It potentially binds to other RNA structures, thus protecting or 
sequestering target structures that stimulate cytoplasmic sensors, thereby establishing a dy-
namic equilibrium between induction and inhibition of innate signalling. Furthermore, it is the 
most considerable target to initiate innate immune response since it is the first viral gene to be 
transcribed. RNA derived from the S segment as for example shown for SNV can be detected 
4 to 6 h p.i. when the hantavirus-related innate response is induced (Hutchinson et al., 1998; 
Schmaljohn and Hjelle, 1997; Hutchinson et al., 1996). In addition, it is the most conserved 
structural protein of hantaviruses and the main target of cellular and humoral immune re-
sponse (Kaukinen et al., 2005). Therefore, the N protein or the corresponding RNA could play 
a pivotal role in interaction with PRRs. 
In fact, different effects on RIG-I signalling could be observed, depending on the origin of the 
N ORF (Figure 28). RIG-I-mediated activation levels of the IFN promotor increased with the 
degree of pathogenicity of the hantavirus strain from which the N protein was derived. The 
highest activation was induced by the DOBV Slo N protein expression plasmid. In contrast, 
only slight but not significant activation could be detected after expression of DOBV Slo N 
protein in combination with MDA5, while the other N protein expression plasmids induced no 
activation or rather diminished IFN-β promotor activity as seen for TULV N (Figure 29). 
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5.2.3.2 Determination of the hantaviral component stimulating RIG-I   
To assess whether the N protein itself or its RNA is the inducing component, the expression 
plasmids were in vitro-transcribed and examined in the same experimental setting (Figure 31). 
Although the fold activations were slightly lower than in the previous described experiments, 
the same induction pattern could be observed, except for DOBV Slo N RNA. The integrity of 
the transcripts has been tested in an RNA gel ensuring that the DOBV Slo N RNA was not 
degraded (Figure 30). A possible explanation could be altered secondary structures of the in 
vitro-transcribed RNA that affect the influence on RIG-I signalling, for example by hiding 
stimulatory motifs or exposing inhibitory sequences. In contrast, in vivo appropriate binding 
of cellular RNA chaperons to DOBV Slo N RNA could allow for the formation of additional 
RIG-I stimulatory structures. Nevertheless, it cannot be entirely excluded that the N protein 
itself also interacts with RIG-I signalling. 
Usually, hantaviral mRNA is capped and tailed by cap snatching mechanism. Accordingly, 
possible 5’-triphosphate ends should only be available in a short time frame for recognition by 
PRRs (Elliott et al., 1991). Since in vitro-transcribed RNA also possess triphosphates at their 
5’ ends that are known as ligands of RIG-I (Hornung et al., 2006), in a subsequent experimen-
tal setting, the transcripts were digested to remove the triphosphates to assess their influence 
on signalling (Figure 33). Activation levels decreased for all digested samples, and the pattern 
also was altered, but still, differences in activation levels could be shown. This observation 
leads to the assumption that certain motifs – maybe in addition to 5’-triphosphates – within 
the RNA and/or the protein derived from the S segment are responsible for activation or even 
inhibition of RIG-I signalling (Figure 31, Figure 33).  
Unfortunately, there was no possibility to verify the amount of 5’-triphosphates for a better 
evaluation of their relevance for signalling induction, but there should not be large differences 
between the samples since all plasmids were treated identically. Furthermore, for example 
JEV mRNA is known to be 5’ capped and no triphosphates are exposed at the 5’ end. How-
ever, it is still detected by RIG-I (Chang et al., 2006; Kato et al., 2006). It has been suggested 
before that RIG-I-mediated RNA recognition is not only dependent on 5’-triphosphates (Cui 
et al., 2008). Motifs inducing or interfering with RIG-I signalling are also liable for viruses, as 
already shown for the 3’-untranslated region of HCV (Saito et al., 2008).  
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5.2.3.3 Definition of a potential RIG-I stimulating motif within the hantaviral N ORF 
To define a potential motif within the N ORF, random deletion mutants of the HTNV N ORF 
with truncated 3’ ends were generated. The candidates were tested for appropriate expression 
and for IFN-β promotor activation through RIG-I signalling (Figure 34). Interestingly, the N 
ORF mutant ∆H1 did not activate the reporter system at all and declined even below negative 
control level, although expression could be proven in Western blot. ∆H2 behaved almost like 
the negative control and was not detectable in Western blot, whereas the third mutant ∆H3 
lacking only a short 3’ end of the ORF reached nearly the IFN-β promotor activation level of 
the full-length plasmid. However, it was expressed much weaker than HTNV N or ∆H1 N. 
Since the deleted sequence is not yet characterised, it is difficult to define the distinct se-
quence or structure which is possibly responsible for activation of RIG-I signalling.  
5.2.3.4 In silico analyses of N ORFs 
For theoretical predictions, sequences of all N ORFs involved in our experiments were sub-
jected to a similarity test in comparison to either DOBV Slo or HTNV N ORF (Figure 39) 
which showed the highest activation levels in our experimental setting. Basically, we hoped to 
see conserved domains for the pathogenic hantavirus strains and/or for the non-pathogenic 
ones. Although homologies could be observed, they do not necessarily correlate with the RIG-
I signalling activation levels. For example, DOBV Slo and DOBV Sk, differing in the strength 
of IFN induction resemble each other strongly. On the other hand, the relations of Murinae- 
and Arvicolinae-associated hantavirus strains are very obvious in the distance plots.   
Therefore, we cannot explain different activation patterns by conserved motifs in the primary 
RNA sequence, and it can be expected that more complex motifs are possibly involved in sig-
nalling induction like for example secondary structures and charges depending on the length 
of the nucleotides. A better knowledge of the binding and activating capacities of RIG-I may 
help to draw conclusions about potential ligands.  
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Figure 39. Distance plots of N ORFs against DOBV Slo and HTNV 
5.2.3.5 Significance of RIG-I for hantaviruses 
We propose that the observed different patterns of RIG-I activation are related to inhibitory or 
stimulatory motifs on the hantaviral RNA molecules as mentioned above. The exact nature of 
these motifs still has to be elucidated, but the activation patterns of phosphatase-treated tran-
scripts and of the deletion mutants suggest that not only the 5’ ends regulate RIG-I and sup-
port the motif hypothesis (Figure 33). Furthermore, viruses that are detected by RIG-I do not 
all possess triphosphates at their 5’ ends or present them only during a very short time frame. 
Although pathogens are characterised by their high diversity, all of them have nucleic acids in 
common (Kato et al., 2006), independent of their modifications. Thus, many cellular detection 
systems make use of the viral genomes during entry or of their products generated by replica-
tion and expression processes of the viruses. For example, endosomally located TLR3 recog-
nises dsRNA independently from its sequence (Alexopoulou et al., 2001; Matsumoto et al., 
2003). Therefore, virus genomes are mostly protected by viral proteins to prevent detection. 
In contrast, mRNA is often uncovered to be accessible for translation complexes. It may be 
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possible that for activation of RIG-I, the 5’-triphosphates of viral RNAs are sufficient and 
necessary whereas for others, intrinsic motifs play an important role. It is also imaginable that 
these motifs show accumulative effects, whether stimulating or inhibiting. Furthermore, there 
are first hints that for longer RNAs, the 5’-triphosphate is less important for detection by RIG-
I, and structures within the sequence play a crucial role.  
The relevance of RIG-I for hantaviruses could also be shown on the functional level. How-
ever, it was not possible to investigate the particular relevance of N ORFs within the context 
of virus infections because up to now a system for reverse genetics is not available for hanta-
viruses. Furthermore, cellular mechanisms responsible for hantavirus detection and subse-
quent triggering of antiviral immune response have not been completely defined either. There-
fore, the impact of N ORF expression on hantavirus-related immune response cannot be 
evaluated yet. Possibly, non-pathogenic hantaviruses trigger innate immunity early as shown 
by different groups (Alff et al., 2006; Kraus et al., 2004; Spiropoulou et al., 2007) because of 
lacking evasion mechanisms whereas pathogenic strains interfere with the immune system 
more aggressively thereby getting the opportunity to replicate more efficiently. In addition, 
different or additional PRRs may be responsible for the recognition of pathogenic and non-
pathogenic hantaviruses, merging in the same signalling cascades to achieve synergistic ef-
fects for virus clearance in simultaneous or successive manners whereas single PRRs show 
only comparatively weak signalling induction.  
5.3 Hantavirus-associated modulation of signalling downstream of PRRs 
After investigating the relations between hantaviral components and innate immune response 
by overexpression of PRRs, the effect on molecules downstream of RIG-I and MDA5 like 
TBK1 and IKKi has been examined. However, the activation levels induced by the tested N 
expression plasmids changed and were not congruent to the RIG-I-related pattern. For over-
expression of both TBK1 and IKKi, TULV declined to inhibition control level whereas PUUV 
activation decreased to the negative control level. Expression plasmids containing N ORFs 
from the two DOBV strains showed similar fold activations. Surprisingly, TBK1 was strongly 
downregulated on protein level in presence of all N protein expression plasmids. It is not clear 
yet whether this finding is due to reduced TBK1 expression which would be surprising con-
sidering the high amounts of transfected TBK1 expression plasmid. Alternatively, antibody 
detection of TBK1 could be impaired by hantaviral nucleocapsid expression (Figure 35).  
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For IKKi, TULV and PUUV N expression plasmids reduced IKKi expression for unknown 
reasons. The weak fold inductions by both plasmids could be explained by the downregula-
tion of IKKi (Figure 36). No induction of the ISRE-coupled luciferase reporter could be ob-
served, although the feedback mediated by IFN secretion should enhance the IFN-β expres-
sion (Figure 37). A possible explanation could be a yet unknown viral evasion mechanism that 
interferes with signalling elements of the feedback loop. Alternatively, a merge of different 
innate signalling cascades triggered by hantaviruses could be necessary for detectable type I 
IFN production. Such synergistic effects may lack in our experimental systems.  
To assess direct interactions and subsequent changes in the localisation of RIG-I by hantaviral 
N protein, co-transfections with RIG-I and N protein expression plasmids derived from 
pathogenic HTNV and non-pathogenic TULV were carried out and analysed by confocal mi-
croscopy. Expression of HTNV N protein led to homogeneous distribution of RIG-I. In con-
trast, co-transfection with TULV N protein resulted in a similar RIG-I localisation as the con-
trol. Thus, HTNV N protein seems to influence the distribution of RIG-I (Figure 38). More 
detailed investigations are necessary to demonstrate a potential interaction, for example by 
immunoprecipitation, and to define the mechanism and subsequent consequences for virus 
and cell.   
5.4 Importance of innate mechanisms upstream from PRRs 
Other mechanisms that may be involved in activation of RIG-I signalling by hantaviruses also 
have to be considered. So far, only the PRRs and the molecules downstream have been dis-
cussed, but upstream molecules and the control of PRR expression could also play a role. 
RNA processing mechanisms could be of importance for PRR signalling since RNAs of dif-
ferent lengths and modifications are potential ligands (Kato et al., 2008). Longer RNA may 
also be less stable, therefore, cellular and viral proteins are possibly involved in forming sec-
ondary RNA structures, providing or hiding potential PAMPs. For viruses, it has been shown 
that MDA5 only recognises EMCV, whereas RIG-I detects RNA viruses with longer ge-
nomes. In general, the precise viral PAMPs are mostly undefined yet for the cytoplasmically 
located PRRs. RIG-I is able to bind double-stranded as well as single-stranded RNA, nucleo-
tide overhangs and 5’ end modifications seem to play a role with varying importance depend-
ing on the RNA length. Recently, a viral motif has been found (Saito et al., 2008), but it is 
difficult to assess the activation potentials of the different PAMPs. Furthermore, it is not yet 
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clear whether PAMPs synergise in the signalling through one or more PRRs. Once more de-
tailed information about these relations becomes available, RNA processing mechanisms lo-
cated upstream of RIG-I and MDA5 and the influence of chaperons will be of special interest.  
5.5 Conclusion and outlook 
The identification of hantaviral nucleocapsid expression as a trigger of RIG-I signalling is a 
further step to a better understanding of hantavirus-related innate immunity. In detail, IFN-β 
promoter activation increases depending on the virulence of the hantavirus strain from which 
the expressed N ORF is derived. More precisely, the N ORF RNA seems to be the component 
responsible for the activation of RIG-I.  
The pathogenicity-dependent activation pattern can be explained by inhibitory or stimulatory 
motifs within the N RNA. Our results give first hints on the nature of such motifs that are 
possibly located at the 3’ end of the N ORF and will be proven by gain- and loss-of-function 
experiments. Furthermore, still unknown PRRs (Paladino et al., 2006) could be involved in 
the detection of hantaviruses as N ORF expressing plasmids or mRNA derived from non-
pathogenic hantaviruses did neither trigger RIG-I nor MDA5 signalling pathways. 
However, it has to be analysed as well whether the low IFN-β promotor activation by some 
expressed N ORFs is the result of missing activation by stimulatory motifs or of active inhibi-
tion by inhibitory structures and the N protein itself. Similarly, the G ORF expression did not 
lead to an activation or an inhibition of RIG-I or MDA5 signalling. Even in vitro-transcribed 
G ORFs, containing 5’-triphosphates, did not trigger IFN promotor signalling, possibly due to 
the reduced importance of 5’-triphosphates for the recognition of longer RNAs by RIG-I.  
Therefore, the discovery of other PRRs involved in hantavirus detection and their degree of 
redundancy would be quite interesting. Induction of innate immunity leads to differential acti-
vation of signal transduction pathways depending on the triggered PRR. Hence, adaptive im-
mune response may vary in strength and efficiency. Our growth kinetics revealed that replica-
tion of non-pathogenic strains was also affected in RIG-I expressing cells compared to cells in 
which RIG-I expression is impaired. To explain these findings, the functions of all hantaviral 
components and their interplay during infection have to be investigated in more depth. Re-
verse genetic systems and appropriate animal models could be of great advantage for such 
studies. In general, partial redundancy of PRRs responsible for hantavirus detection would not 
be surprising for the induction of an important antiviral defence system like the type I IFN 
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response and for the benefit of synergistic effects. However, the delicate regulation mecha-
nisms of the type I IFN system do not simplify respective investigations. The role of IFN is 
ambiguously critical for the host since it has to operate fast to contribute successfully to virus 
clearance, but a prolonged expression can also lead to autoimmune reactions (Le Bon et al., 
2003; Ronnblom et al., 2006; Taniguchi and Takaoka, 2001).  
In addition, RIG-I and MDA5 signal transduction may not “only” be involved in IFN induc-
tion, but also other pathways. For example, their adaptor molecule MAVS seems to be in-
volved in regulation of apoptosis and of surface molecules (Kumar et al., 2006). 
Furthermore, differences in PRR distribution and function do not only occur in different cell 
types of the same organism, but also in comparable cell types of different species. This fact is 
of special interest for the comparison of hantavirus-related immune response in reservoir 
hosts and humans: hantaviral infection remains apathogenic in rodents and persists, whereas 
in humans, the virus is cleared under (partially severe) courses of disease (Botten et al., 2000).  
All these analyses may contribute to an understanding of differences in immune responses and 
divergent cytokine expression patterns caused by hantaviruses differing in virulence towards 
humans. Thus, they could build a basis for a better understanding of the differences in severity 
of clinical symptoms and furthermore elucidate the asymptomatic persistence in reservoir 
hosts. Finally, these findings could help to develop improved treatments after hantaviral infec-
tion or prophylactic means like vaccines.  
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